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Glucose oxidationCardiac ischemia and its consequences including heart failure, which itself has emerged as the leading cause
of morbidity and mortality in developed countries are accompanied by complex alterations in myocardial
energy substrate metabolism. In contrast to the normal heart, where fatty acid and glucose metabolism are
tightly regulated, the dynamic relationship between fatty acid β-oxidation and glucose oxidation is
perturbed in ischemic and ischemic–reperfused hearts, as well as in the failing heart. These metabolic
alterations negatively impact both cardiac efﬁciency and function. Speciﬁcally there is an increased reliance
on glycolysis during ischemia and fatty acid β-oxidation during reperfusion following ischemia as sources of
adenosine triphosphate (ATP) production. Depending on the severity of heart failure, the contribution of
overall myocardial oxidative metabolism (fatty acid β-oxidation and glucose oxidation) to adenosine
triphosphate production can be depressed, while that of glycolysis can be increased. Nonetheless, the balance
between fatty acid β-oxidation and glucose oxidation is amenable to pharmacological intervention at
multiple levels of each metabolic pathway. This review will focus on the pathways of cardiac fatty acid and
glucose metabolism, and the metabolic phenotypes of ischemic and ischemic/reperfused hearts, as well as
the metabolic phenotype of the failing heart. Furthermore, as energy substrate metabolism has emerged as a
novel therapeutic intervention in these cardiac pathologies, this review will describe the mechanistic bases
and rationale for the use of pharmacological agents that modify energy substrate metabolism to improve
cardiac function in the ischemic and failing heart. This article is part of a Special Issue entitled: Mitochondria
and Cardioprotection.hondria and Cardioprotection.
search Centre, Departments of
entistry, University of Alberta,
170; fax: +1 780 492 9753.
paschuk).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
The high energy requirements of the myocardium are evidenced by
thehigh ratesof adenosine triphosphate (ATP) synthesis andhydrolysis.
Myocardial ATP stores are relatively low compared to the amountofATP
required to sustain cardiac contraction, basal metabolism, and ionic
homeostasis. As a result, there is a nearly complete turnover of the
myocardial ATP pool every 10 s [1], with the heart cycling approxi-
mately 6 kg of ATP on a daily basis [2]. To meet these high energy
demands, the normal heart possesses a high degree of metabolic
ﬂexibility, which is demonstrated by its ability to utilize various energy
substrates including fatty acids, glucose, lactate, and ketone bodies to
generate ATP. The contribution of each of these energy substrates toATPgeneration is tightly regulated, and there is a signiﬁcant degree of
plasticity and interdependence between energy substrates utilized.
Under normal physiological conditions, fatty acids and carbohydrates
(i.e. glucose and lactate) represent the primary metabolic fuels that
sustain cardiac function, and upwards of 95% of ATP production is
attributable to mitochondrial oxidative phosphorylation. In the normal
adult heart, fatty acid β-oxidation accounts for 60–80% of ATP
production [1,3–5], with the remainder being primarily accounted for
by carbohydrate (glucose and lactate) oxidation, and the oxidation of
ketone bodies.
Various cardiac pathological states can cause perturbations of the
tightly regulated pathways of myocardial energy substrate metabo-
lism, and these perturbations can contribute to the progression of
myocardial injury. Ischemic heart disease(s) (including, but not
limited to angina and myocardial infarction) occur when coronary
blood ﬂow is inadequate. As the heart extracts 70–80% of the
molecular oxygen (O2) per unit of blood delivered [6,7], myocardial
ischemia occurs when O2 availability is not sufﬁcient to meet the O2
requirements of the heart. The consequences of myocardial ischemia
are dependent on the nature and severity of the ischemic episode, and
the elapsed time to the subsequent re-establishment of coronary ﬂow
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include alterations in cardiac structure, deﬁcits in cardiac mechanical
function, and perturbations in energy substrate metabolism.
In Western society there has been a marked improvement in the
number of patients surviving the deleterious consequences of myocar-
dial ischemia, which has been attributed predominantly to improved
therapies (i.e. evidence based pharmacological therapy, thrombolysis/
thrombolytic therapy, and reﬁnements in revascularization) and to a
decreased prevalence of cardiovascular risk factors (e.g. hypertension,
hypercholesterolemia, and smoking) [8,9]. However, with these
improvements in survival there has been a concomitant increase in the
prevalence of heart failure. Heart failure is a complex clinical syndrome,
the etiology of which generally stems from pre-existing ischemic heart/
coronary artery disease, or it is of non-ischemic and/or idiopathic origin
[10,11]. Heart failure is characterized by the progressive inability of the
heart to ﬁll with, and eject adequate amounts of blood tomeet the needs
of the body [12,13]. Heart failure has emerged as the leading cause of
morbidity andmortality in developed countries [14]. In addition to being
accompanied by characteristic neuro-hormonal alterations including
activation of the renin–angiotensin–aldosterone system (RAAS) and
activationof thesympathetic nervous system [15,16]; heart failure is also
accompanied by distinct alterations in energy substrate metabolism.
Classically, the treatment of ischemic heart disease and heart
failure has focused on the use of pharmacological agents that alter
systemic and/or cardiac hemodynamics. As knowledge of the
mechanisms regulating cardiac energy substrate metabolism
increases, and as alterations in energy substrate metabolism attend
the above cardiac pathophysiologies, the modulation and optimiza-
tion of energy substrate metabolism represents a novel and promising
area for therapeutic intervention in ischemic heart disease and heart
failure. The aim of this review is to present: i) an overview of cardiac
energy substrate metabolism, ii) the metabolic phenotype of the
ischemic/ischemic–reperfused heart, iii) the metabolic phenotype of
the failing heart, and iv) the mechanistic rationale for the use of
pharmacological agents that modify energy metabolism to limit the
deleterious consequences of ischemic heart disease and heart failure.
2. Cardiac energy substrate metabolism
In the aerobic settinggreater than90%of theATPproduced in theheart
is derived frommitochondrial oxidative phosphorylation [10,11]. Reduc-
ing equivalents (protons and electrons) are transferred from various
energy substrates to the mitochondria by the reduced forms of ﬂavin
adenine dinucleotide (FADH2) and nicotinamide adenine dinucleotide
(NADH), generatedbydehydrogenase reactionsoccurring in the fatty acid
β-oxidation pathway, the tricarboxylic acid (TCA) cycle, and during the
oxidative disposal of pyruvate (i.e. glucose oxidation). The extents to
which the various metabolic pathways contribute to myocardial ATP
production are dependent on energetic demand, which itself is
determinedby chronotropic and inotropic state, preload, and the systemic
vascular resistance against which the heart must eject blood [10].
2.1. Fatty acid utilization
In the cytosolic compartment, free fatty acids (FFAs) require
activation prior to further metabolism. FFAs are activated via
esteriﬁcation to CoA, which generates a fatty acyl-CoAmoiety through
an ATP dependent process catalyzed by a family of fatty acyl-CoA
synthase (FACS) enzymes. In the cytosol, acyl-CoA molecules are
bound to acyl-CoA binding protein (ACBP), and can have a number of
different metabolic fates including use for phospholipid and triacyl-
glycerol synthesis, signal transduction, or mitochondrial fatty acid β-
oxidation [10]. The inner mitochondrial membrane is impermeable to
fatty acyl-CoA molecules, and the mitochondrial uptake of fatty acyl-
CoAs is thus mediated by a complex of proteins utilizing carnitine as a
shuttle mechanism [17]. Carnitine palmitoyl-transferase I (CPTI) islocalized to the outer mitochondrial membrane and converts fatty
acyl-CoA molecules to their respective fatty acylcarnitine moieties
[18,19], which are subsequently shuttled into the mitochondrial
matrix space by carnitine translocase, and reconverted back to a fatty
acyl-CoAmoiety by carnitine palmitoyl-transferase II (CPTII), which is
localized to the inner leaﬂet of the inner mitochondrial membrane
[20–22]. In the mitochondrial matrix, fatty acyl-CoA (saturated acyl-
chain) molecules are progressively dismembered through the process
of fatty acid β-oxidation by the sequential action of the enzymes acyl-
CoA dehydrogenase, enoyl-CoA hydratase, 3-L-hydroxyacyl-CoA de-
hydrogenase, and 3-ketoacyl-CoA thiolase. Polyunsaturated and
monounsaturated fatty acids (e.g. oleate) require auxiliary enzymes
including 2,4-dienoyl-CoA reductase and enoyl-CoA isomerase which
facilitate the generation of a trans double-bond [23], a prerequisite for
fatty acid β-oxidation by the four major enzymes described. Fatty acid
β-oxidation sequentially shortens fatty acyl-CoA molecules by 2
carbon units through the liberation of acetyl-CoA (which is further
metabolized in the TCA cycle), while also generating reducing
equivalents (NADH and FADH2) which act as electron donors for the
electron transport chain and the process of oxidative phosphorylation.
Important factors regulating the rate of fatty acidβ-oxidation are the
level of circulating FFA in the plasma and the intracellular level of
malonyl-CoA [24,25]. The concentration of FFA in the plasma is
dependent on both prandial and hormonal state. Circulating FFA
concentrations increase with fasting, while decreasing in the post-
prandial state due in part to the anabolic and anti-lipolytic effects of
insulin [26–28]. An increase in catecholamine discharge (e.g. during
ischemic or surgical stress) also increases the circulating FFA concen-
tration by increasing lipolysis. One of the consequences of increased FFA
delivery to the heart is an increase in the rate of fatty acidβ-oxidation. In
addition to being regulated by the availability of circulating FFA, the
activities of the enzymes of mitochondrial fatty acid β-oxidation also
inﬂuence the overall rates of fatty acid utilization [11,29]. The acyl-CoA
dehydrogenase and 3-hydroxyacyl-CoA dehydrogenase enzymes are
both sensitive to the ratios of FAD/FADH2 and NAD+/NADH in the
mitochondrial matrix, and the enzyme 3-ketoacyl-CoA thiolase is
sensitive to the mitochondrial acetyl-CoA/CoA ratio.
Malonyl-CoA is an endogenous regulator of fatty acid β-oxidation
[30,31]. The intracellular levels of malonyl-CoA are determined by
energy demand and its rates of synthesis and degradation. Malonyl-
CoA is synthesized from cytosolic acetyl-CoA via acetyl-CoA carbox-
ylase (ACC), while being degraded via malonyl-CoA decarboxylase
(MCD) [30,31]. The activity of ACC is under phosphorylation control
by 5′-AMP activated protein kinase (AMPK), a kinase thatmodiﬁes the
activity of a number of metabolic enzymes involved in regulating both
fatty acid and glucose metabolism [32–35]. In addition, AMPK is also
implicated in upregulating various energy producing processes [36–
40], and as such is central in the regulation of energy substrate
metabolism. Mitochondrial acetyl-CoA, via the formation of acetyl-
carnitine can be transported into the cytosol, and acetylcarnitine can
subsequently be reconverted back to acetyl-CoA by the action of
cytosolic carnitine acetyl transferase [41]. In addition, citrate also
inﬂuences malonyl-CoA levels. A proportion of citrate that escapes
oxidation in the mitochondrial matrix by the TCA cycle, can utilize the
mitochondrial tricarboxylate transporter to translocate to the cyto-
solic compartment, where it can allosterically activate ACC [42] or
serve as a contributor to cytosolic acetyl-CoA via the ATP citrate lyase
reaction [43,44]. Malonyl-CoA regulates fatty acid β-oxidation by
inhibiting the activity of CPTI [45–47], the rate limiting enzyme of
mitochondrial fatty acid uptake, thereby controlling the entry of fatty
acids into the mitochondria for subsequent oxidation.
2.2. Glucose utilization
The stimulation ofmyocardial glucose transport involves an increase
in the recruitment of GLUT1 as well as GLUT4 from intracellular
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cytosolic compartment, the enzymes hexokinase I and/or hexokinase
II phosphorylate glucose, thereby generating glucose-6-phosphate (G-
6-P). Interestingly, during fetal life, GLUT1 [49,50] and hexokinase (HK)
I [49] are the predominant glucose transporter and HK isoforms present
in the heart, but following birth, cardiac GLUT1/HK I expression
decreases, while GLUT4 expression and HK II expression increases
[49,50]. As the failing heart reverts to a fetal metabolic phenotype, the
expressionof distinctGLUT andhexokinase isoformsmay be involved in
determining metabolic proﬁle (see Section 5.1). G-6-P is effectively
trapped in the cell as a substrate for either of two metabolic fates,
storage in the form of glycogen, or catabolism by glycolysis.
Glycolysis is the biochemical process that, in the cytosol, converts
glucose to lactate or pyruvate under anaerobic or aerobic conditions,
respectively. There is a net production of 2 moles (mol) ATP/1 mol of
exogenous glucose that passes through glycolysis. The enzyme 6-
phosphofructo-1-kinase (PFK-1) is the ﬁrst regulatory site that
commits glucose to catabolism by glycolysis [51]. Flux through PFK-
1 is allosterically inhibited by ATP, citrate, and protons [51].
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the ﬁrst en-
zyme of the ATP generating stage of glycolysis, is involved in the
oxidation and phosphorylation of glyceraldehyde phosphate coupled
to the production of NADH from NAD+ [52]. To ensure that ﬂux
through GAPDH is not limited NADH must be continually reoxidized
to NAD+, which can be accomplished by one of two routes. In the
absence of O2, NADH is reoxidized by the enzyme lactate dehydro-
genase (LDH), which converts pyruvate to lactate, whereas in the
presence of O2, NADH is reoxidized by the malate/aspartate shuttle
and mitochondrial electron transport chain.
Pyruvate oxidation (i.e. glucose oxidation) requires pyruvate
transport into the mitochondria via a monocarboxylate carrier [53].
In the mitochondrial matrix, pyruvate can be carboxylated; however,
in the heart the majority of pyruvate undergoes oxidative decarbox-
ylation by the pyruvate dehydrogenase (PDH) complex yielding
acetyl-CoA [54–56]. The PDH complex consists of PDH itself, PDH
kinase (PDK), and PDH phosphatase, and is regulated both by its
substrates and products (i.e. substrate/product ratios), and by
covalent modiﬁcation [57–59]. Generally only a small fraction
(~20%) of PDH is in the active form, and this proportion is increased
in response to an increase in glycolytic ﬂux (and hence an increased
generation of pyruvate), or in response to increased cardiac workload
or catecholamine stimulation. PDH is also sensitive to inhibition by its
products, as an increase in either the ratio of NADH/NAD+ and/or
acetyl-CoA/CoA decreases the rate of pyruvate decarboxylation
[57,60,61]. With respect to covalent modiﬁcation, PDH phosphatase
dephosphorylates and activates PDH, whereas PDH kinase (PDK), in
response to acetyl-CoA and NADH phosphorylates and inhibits PDH,
thereby restricting the oxidation of carbon units derived from
glycolysis [57,60].
2.3. Energy substrate competition — the glucose/fatty acid cycle
The reciprocal relationship between fatty acids and glucose for
oxidative metabolism (glucose/fatty acid cycle) was originally
described by Randle et al. in 1963 [28]. The molecular mechanisms
underlying the glucose/fatty acid cycle are apparent at various stages
of the pathways involved in the catabolism of each substrate (Fig. 1).
Acetyl-CoA and NADH produced from fatty acid β-oxidation inhibit
the PDH complex. Citrate derived from fatty acid ß-oxidation-derived
acetyl-CoA can inhibit PFK-1 which in turn can lead, albeit to a lesser
extent, to an inhibition of hexokinase by G-6-P [27]. As the inhibition
of PDH is the most signiﬁcant consequence of elevated rates of fatty
acid β-oxidation, the effect of high fatty acid β-oxidation rates is an
uncoupling between the rates of glycolysis and subsequent glucose
oxidation (pyruvate oxidation). As pyruvate is a charged species, its
transport across the inner mitochondrial membrane requires the co-transport of protons in a 1:1 stoichiometric manner [53,62], following
which pyruvate is oxidized by the PDH complex. Therefore, when the
rates of glycolysis are uncoupled from glucose oxidation protons
produced from the hydrolysis of glycolytically derived ATP are not
coupled to pyruvate co-transport across the inner mitochondrial
membrane, and can thus produce intracellular acidosis [63,64]. The
uncoupling of glucose metabolism, especially during periods of
ischemia when blood ﬂow is insufﬁcient to remove metabolic by-
products, can inﬂuence cardiac ionic homeostasis and cardiac
efﬁciency (see Sections 3 and 4).
Conversely, increasing the contribution of glucose oxidation to the
generation of acetyl-CoA can decrease fatty acid β-oxidation via
feedback inhibition of 3-ketoacyl-CoA thiolase, while NADH derived
from glucose oxidation can decrease fatty acid β-oxidation via
feedback inhibition of both acyl-CoA dehydrogenase and 3-hydro-
xyacyl-CoA dehydrogenase. Furthermore, an increase in glucose-
derived acetyl-CoA, via the actions of the enzymes carnitine
acetyltranferase [11,65] and ACC can increase the synthesis of
cytosolic malonyl-CoA, a negative regulator of mitochondrial fatty
acid uptake and oxidation. Also, increasing glucose oxidation
improves the coupling of glucose metabolism, and hence decreases
proton production. The reciprocal inhibition of fatty acid β-oxidation,
and decreases in proton production attributable to increased glucose
oxidation have the potential to inﬂuence cardiac efﬁciency.
3. Cardiac energy substrate metabolism and cardiac efﬁciency
Cardiac mechanical efﬁciency, deﬁned originally by Bing et al. [66]
refers to the relationship between mechanical energy generated (i.e.
cardiac work) and energy consumed (i.e. oxygen consumption —
MVO2) by the ventricle during contraction, and is expressed as the
work/MVO2 ratio. As cardiac muscle, under aerobic conditions meets
the majority (N95%) of its energetic requirements via the oxidation of
fatty acids and carbohydrates [11], MVO2 provides a sufﬁcient
measure of energy input for contraction. Also, as the rates of cardiac
energy metabolism are tightly coupled to energy demand, there is a
good correlation between MVO2 and cardiac work [67,68]. Recent
reports point to the importance of metabolism in determining cardiac
efﬁciency [69]. Cardiac contraction is driven by the hydrolysis of ATP,
the vast majority of which is formed from mitochondrial oxidative
phosphorylation (N95% under aerobic conditions), as such, cardiac
efﬁciency is inﬂuenced by the efﬁciency of ATP generation and the
efﬁciency of converting the chemical energy of ATP hydrolysis into
mechanical work. These factors in turn are inﬂuenced by the intrinsic
nature of the energy substrate (fatty acid vs carbohydrate) oxidized.
Altering cardiac efﬁciency by targeting the balance between fatty acid
β-oxidation and glucose oxidation may represent a suitable thera-
peutic intervention in the treatment of both ischemic heart disease
(see Sections 4 and 6) and heart failure (see Sections 5 and 6).
3.1. Phosphorous/oxygen ratios and the efﬁciency of ATP generation
Phosphorous/oxygen (P/O) ratios of oxidative phosphorylation
deﬁne the number of molecules of ATP produced per atom of oxygen
reduced by the mitochondrial electron transport chain [70], and differ
depending on the type of energy substrate utilized for the generation
of mitochondrial NADH and FADH2. Comparing palmitate and glucose
as energy substrates, the complete oxidation of one palmitate
molecule generates 105 molecules of ATP, while the complete
oxidation of one molecule of glucose generates 31 molecules of ATP.
Although fatty acid β-oxidation clearly generates the larger amount
ATP, it comes at the expense of a greater oxygen requirement than
carbohydrate oxidation. The P/O ratio of palmitate is less than that of
glucose, making palmitate a less efﬁcient substrate for ATP synthesis.
Therefore, at any given level of cardiac work, an increased depen-
dence on fatty acids relative to carbohydrates as an oxidative fuel
Fig. 1. The glucose/fatty acid cycle. The glucose/fatty acid cycle describes the reciprocal relationship between fatty acid and glucose metabolism. Acetyl-CoA and the reduced form of
nicotinamide adenine dinucleotide (NADH) produced from fatty acid β-oxidation can inhibit the pyruvate dehydrogenase (PDH) complex (1). Citrate derived from fatty acid β-
oxidation-derived acetyl-CoA inhibits phosphofructokinase-1 (PFK-1), the rate determining step of glycolysis, which in turn can lead to an inhibition of hexokinase by glucose-6-
phosphate (G-6-P) (2). Increasing the contribution of glucose oxidation to the generation of acetyl-CoA decreases fatty acid β-oxidation via feedback inhibition of 3-ketoacyl-CoA
thiolase, in addition, NADH derived from glucose oxidation can decrease fatty acid β-oxidation via feedback inhibition of both the acyl-CoA dehydrogenase and 3-hydroxyacyl-CoA
dehydrogenase reactions (3).
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stages of heart failure) decreases cardiac efﬁciency. Cardiac efﬁciency
only differs by a theoretical value of 10–13% when calculated on the
basis of P/O ratios using exclusively palmitate or glucose as an
oxidative fuel. However, reported differences aremuch larger, ranging
from 25–40%, suggesting there are additional mechanisms by which
the balance between fatty acid and carbohydrate oxidation inﬂuences
cardiac efﬁciency.
3.2. Uncoupling proteins and cardiac efﬁciency
The synthesis of ATP via oxidative phosphorylation is dependent
on the electrochemical proton gradient across the inner mitochon-
drial membrane, generated by the translocation of protons from the
mitochondrial matrix to the intermembrane space by complexes I, III,
and IV of the electron transport chain [70,71]. The subsequent
movement of protons down the electrochemical gradient via the F1/F0
ATPase into the mitochondrial matrix provides the chemical energy
required for ATP synthesis [71]. Uncoupling proteins (UCP1–UCP5)
are a family of mitochondrial proteins that provide an alternate route
for the movement of protons from the intermembrane space to the
matrix that is uncoupled from ATP synthesis. Ventricular muscle
primarily expresses UCP2 and UCP3, with recent reports implicating
UCP3 in regulating fatty acid-induced uncoupling of oxidative
phosphorylation [72,73]. These effects may contribute to themechanisms responsible for the decreased efﬁciency of ATP genera-
tion with the use of fatty acids as an oxidative fuel. Interestingly,
recent reports demonstrate a positive correlation between circulating
FFA concentrations and the expression of both UCP2 and UCP3 in the
failing heart [74], which may uncouple oxidative phosphorylation,
thereby decreasing ATP synthesis and cardiac efﬁciency [75].
Increased cardiac fatty acid utilization in hearts from insulin-
resistant/diabetic ob/ob and db/db mice is associated with increased
MVO2, and uncoupled mitochondrial respiration, effects that also
decrease rates of ATP synthesis and cardiac efﬁciency [76–80]. The
decrease in cardiac efﬁciency may be attributed to increased MVO2
[76,78,79], decreased LV work [77,80] or a combination of both
[77,80].
3.3. Futile cycling of fatty acid intermediates and cardiac efﬁciency
Although equivocal [81], an additional role of UCP3 is the export of
fatty acid anions from the mitochondrial matrix, an effect which may
contribute to the futile cycling of fatty acid intermediates, and hence
ATP wasting in the presence of elevated fatty acid utilization. When
the supply of fatty acyl-CoA to the mitochondria exceeds the capacity
to utilize it via fatty acid β-oxidation [82] mitochondrial thioesterase
enzymes (MTEs) can hydrolyze surplus fatty acyl-CoA yielding free
CoA and fatty acid anions. As mitochondria cannot regenerate the
fatty acyl-CoA moiety, the fatty acid anion is proposed to be exported
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function of UCPs, in conjunction with mitochondrial thioesterases
may protect against the accumulation of potentially deleterious fatty
acid anions in thematrix, as well as preventing the depletion of matrix
CoA [83]. However, this would be associated with a signiﬁcant ATP
wasting effect as the exported fatty acid anion requires activation/
esteriﬁcation prior to further metabolism. This requires the action of
acyl-CoA synthase. This reaction consumes the equivalent of 2 ATP
molecules as it releases AMP and PPi, and as such does not generate
ADP (which can be salvaged to ATP by the adenylate kinase reaction).
Fatty acids can also cycle between their acyl-CoA moieties and the
intracellular triacylglycerol pool [84,85]. The cycling between acyl-
CoA species and triacylglycerol has been reported to account for
approximately 30% of total cellular energy expenditure [86]. This is
attributed to the requirement for ATP-dependent re-esteriﬁcation of
fatty acids liberated from the triacylglycerol pool prior to subsequent
β-oxidation or for the subsequent re-incorporation into the triacyl-
glycerol pool. Futile cycling via these routes contributes to decreased
cardiac efﬁciency by decreasing the efﬁciency of converting ATP
hydrolysis to contractile work when fatty acid utilization is increased.
Although direct evidence for this type of futile cycling is lacking in the
ischemic and failing heart, it nonetheless may provide a possible
mechanism contributing to the observed deﬁcits in cardiac efﬁciency.
4. Metabolic phenotype of ischemic and ischemic–reperfused
hearts
Various forms of ischemic heart disease including angina pectoris,
acute myocardial infarction, and heart failure profoundly affect
cardiac energy substrate metabolism and function. In the ischemic
myocardium there is a rapid loss of contractile force, a depletion of
high energy phosphates, and disturbances of ionic homeostasis.
Alterations in the availability of oxygen and circulating energy
substrates, as well as alterations in the mechanisms regulating
substrate metabolism contribute to the metabolic phenotype(s)
during both ischemia and reperfusion with respect to the utilization
of carbohydrates and fatty acids, which in turn impact cardiac
efﬁciency and function.
4.1. Anaerobic glycolysis
Glycolysis becomes a very important source of energy during
ischemia due to its ability to generate ATP in the absence of O2 (Fig. 2).
Although glycolytic ATP production may be sufﬁcient to maintain/
correct ionic homeostasis during mild to moderate ischemia, the
hydrolysis of glycolytically-derived ATP uncoupled from subsequent
pyruvate oxidation leads to the increased generation of lactate and
protons. During severe/total ischemia, due to a lack of blood ﬂow, the
metabolic by-products of glycolysis are not removed, and ﬂux through
the pathway is eventually inhibited due to the accumulation of
protons (intracellular acidosis) at the level PFK-1 and GAPDH [52,87].
These effects can further aggravate disturbances in ionic homeostasis.
Decreased ATP production during ischemia compromises the
function of various ATPase enzymes involved in regulating ionic
homeostasis. Impaired activity of the Na+/K+ ATPase, which extrudes
3 Na+ ions in exchange for 2 K+ ions [88] leads to intracellular Na+
overload. Impaired activity of the sarcolemmal and sarcoplasmic Ca2+
ATPaseswhich are responsible for the extrusion and reuptake of Ca2+ into
the sarcoplasmic reticulum, respectively, leads to intracellular Ca2+
overload [89]. Intracellular acidosis also impairs myoﬁlament responsive-
ness to Ca2+, thereby contributing to the loss of contractile force during
ischemia, and can contribute to impaired recovery of post-ischemic
mechanical function. The accelerated rates of glycolysis characteristic of
the ischemic period can resolve during reperfusion [90–92], and still
remain uncoupled from glucose oxidation.4.2. Fatty acid β-oxidation and carbohydrate oxidation
Factors including prandial state and catecholamine discharge
affect the concentration of circulating FFA. Plasma FFA concentration
is elevated in the fasting state, while it is decreased in the post-
prandial state due to an insulin-induced inhibition of adipose tissue
lipolysis [27,28]. Ischemic stress increases catecholamine discharge,
and plasma norepinephrine (NE) levels. Depending on the severity of
the ischemic insult, catecholamine levels can remain elevated for
prolonged periods of up to 24 h [93]. Catecholamines stimulate
adipose tissue lipolysis, decrease pancreatic insulin release, and
decrease peripheral insulin sensitivity [94–96]. Ischemic stress is
also accompanied by elevated plasma levels of hydrocortisone, which
can blunt insulin sensitivity [97]. Taken together these alterations
have permissive effects on adipose tissue lipolysis leading to
increased plasma concentrations of FFA and increased delivery of
FFA to the myocardium. The increased delivery of FFA to the
myocardium can alter fatty acid utilization during both ischemia,
and reperfusion following ischemia.
The prerequisite for oxygen in the process of oxidative phos-
phorylation results in a rapid decline in ATP production from fatty
acid β-oxidation and glucose oxidation that is proportional to the
degree of ischemia. Nonetheless, fatty acid β-oxidation remains the
predominant process for residual oxidative metabolism [98–101].
The decrease in glucose oxidation during ischemia necessitates a
rapid acceleration in the conversion of pyruvate to lactate via LDH in
order to regenerate NAD+ under anaerobic conditions, which is
required to maintain glycolytic ﬂux through GAPDH. In the case of
total ischemia, NADH, and FADH2 can accumulate [102], and inhibit
the acyl-CoA dehydrogenase and 3-hydroxyacyl-CoA dehydrogenase
enzyme reactions of fatty acid β-oxidation [1]. Also, acylcarnitine
species can accumulate in both the mitochondrial matrix and
cytosolic compartments, while acyl-CoA species can accumulate
primarily in the mitochondrial matrix [103]. The accumulation of
acylcarnitine and acyl-CoA species can promote the disruption of
mitochondrial cristae, and the formation of amorphous intramito-
chondrial densities. These changes in mitochondrial ultrastructure
may ultimately disrupt mitochondrial function [104].
In the post-ischemic period, the rates of fatty acid β-oxidation
rapidly recover to near pre-ischemic values, whereas the rates of
glucose oxidation, cardiac efﬁciency, and mechanical function remain
depressed [92,105,106]. Furthermore, as reperfusion rapidly nor-
malizes extracellular pH, it generates a large trans-sarcolemmal
proton gradient that increases Na+/H+ exchange and exacerbates
intracellular Na+ overload incurred during ischemia. In turn, Na+
overload promotes reverse mode activation of the Na+/Ca2+
exchanger, which extrudes 3 Na+ in exchange for 1 Ca2+, thereby
contributing to intracellular Ca2+ overload during reperfusion
[89,107]. These disturbances in ionic homeostasis during ischemia
and in the post-ischemic period during reperfusion contribute to
deﬁcits in both cardiac function and cardiac efﬁciency, both of which
can be improved by therapies that optimize myocardial energy
substrate metabolism.
5. Metabolic phenotype of the failing heart
Heart failure is characterized by alterations in cardiac hemody-
namics and reﬂex neuro-endocrine activation (sympathetic nervous
system, renin–angiotensin aldosterone system) secondary to de-
pressed contractile function. Experimentally, heart failure can be
induced in response to volume-overload, pressure-overload, rapid
ventricular pacing, genetic alterations (transgenic animals), or
myocardial infarction [108,109]. As such, multiple cardiovascular
diseases including ischemic heart disease(s), hypertension, as well as
cardiomyopathies of genetic origin can progress, ultimately to heart
failure. As heart failure itself progresses to its advanced stages,
Fig. 2. Alterations in myocardial energy substrate metabolism in ischemia/reperfusion. During ischemia, glycolysis becomes an important source of ATP production in response to a
decrease in the supply of oxygen, or in the absence of oxygen (1). Fatty acids dominate as the substrate for residual oxidative metabolism due to increased plasma levels of fatty acids
(2) as well as the activation of 5′-adenosine monophosphate activated protein kinase (AMPK) which decreases the production of malonyl-CoA, the endogenous inhibitor of carnitine
palmitoyl-transferase-I (CPTI) (3). During reperfusion, glycolytic rates remain high, while fatty acid oxidation dominates over glucose oxidation as the main source of oxidative
metabolism. The dominance of fatty acid oxidation during reperfusion inhibits glucose oxidation (4). The uncoupling of glycolysis from glucose oxidation leads to increased proton
production, which ultimately leads to myocardial acidosis and calcium overload (5).
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ATP content in the normal heart, [110–113], in addition there are
decreases in creatine Cr and phosphocreatine PCr content (see for
review [2,114,115]). Furthermore, the PCr/ATP ratio is decreased in
heart failure and correlates well with New York Heart Association
(NYHA) functional class [116]. Defects in the rates of oxygen
consumption and mitochondrial electron transport chain activity,
which impact oxidative phosphorylation, and hence ATP generation
accompany the advanced stages of heart failure (see for review
[2,11]). Such deﬁcits in energy generating processes and energetic
intermediates suggest that alterations in energy substratemetabolism
are important biochemical hallmarks of, and contributors to the
pathogenesis and progression of heart failure.
5.1. Reversion to the fetal metabolic proﬁle
Pathological hypertrophy is maladaptive, and progresses to heart
failure. Pathological cardiac hypertrophy results in a number of
cellular changes, including alterations in contractile proteins [117–
120]. Furthermore, it is now apparent that pathological hypertrophyin the mature heart is accompanied by a reversion to a fetal pattern of
energy substrate metabolism [118,119,121]. Speciﬁcally, glycolysis
increases in pressure-overload cardiac hypertrophy [122–124], while
fatty acid oxidation decreases [122,125,126]. These effects are
accompanied by parallel changes in the activity and/or expression of
enzymes involved in these metabolic pathways [120,127,128].
Members of the peroxisome proliferator activated receptor (PPAR)
superfamily are involved in regulating fatty acid metabolism. There
are three distinct isoforms of PPAR (PPARα, PPARβ/δ, and PPARγ), and
each has distinct cardiovascular effects. PPARα is predominantly
expressed in the heart, muscle, and liver, PPARβ is expressed in a
more ubiquitous manner, with high levels in both cardiac and skeletal
muscle, while PPARγ is predominantly expressed in adipose tissue
and exists at lower levels in cardiac and skeletal muscle [129]. The
peroxisome proliferator activated receptor (PPAR) isoforms PPARα
and PPARβ/δmay inﬂuence the fetal metabolic phenotype observed in
the presence of pathological cardiac hypertrophy. Genetic deletion of
PPARα is associated with cardiac hypertrophy, and decreased rates of
fatty acid β-oxidation [130]. PPARα and peroxisome proliferator
activated receptor γ coactivator (PGC)-1α levels are also decreased in
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myocyte PPARα suppresses hypertrophy by attenuating increases in
protein synthesis [132,133], and also prevents the downregulation of
the expression of the muscle isoforms of CPTI [133]. However, the
precise role of the PPARα in cardiac hypertrophy/failure has not been
completely resolved. Speciﬁcally, although cardiac-speciﬁc over-
expression of PPARα increases myocardial fatty acid β-oxidation
[134], it is also associated with cardiac hypertrophy [134,135].
Cardiac-speciﬁc ablation of PPARβ/δ is also accompanied by decreased
myocardial fatty acid β-oxidation [136]. Interestingly, cardiac speciﬁc
overexpression of PPARβ/δ does not increase myocardial fatty acid
oxidation; however, it does increase glucose oxidation, an effect
associated with the increased expression of cardiac GLUT4 [137]. This
effect may be related to the ability of PPARβ/δ to improve insulin
sensitivity [138,139]. The lack of change in fatty acid β-oxidation in
response to PPARβ/δ overexpression may be attributable to the
reciprocal relationship between fatty acid and carbohydrate oxidation
described by the glucose/fatty acid cycle.
In the hypertrophied heart there is an increase in glycolysis
[122,140], which is accompanied by increased expression levels of
GLUT1 [141], and increased activity of the glycolytic enzyme enolase
[142]. Despite the acceleration of glycolysis, glucose and lactate
oxidation rates remain low [122]. Recent reports indicate that this
may be due to a compensatory increase in pyruvate carboxylation via
malic enzyme and pyruvate carboxylase required to replenish the TCA
cycle by anaplerosis in the setting of cardiac hypertrophy [56].
Therefore, there is a reversion to the fetal metabolic proﬁle, where
ATP production is more dependent on glycolysis and less so on fatty
acid β-oxidation and glucose oxidation in the setting of pathological
hypertrophy, which itself can progress to heart failure.
5.2. Myocardial fatty acid and glucose utilization in heart failure
Alterations in energy substrate metabolism accompanying heart
failure are extremely complex, in part due to the heterogeneous
nature of heart failure itself. Speciﬁcally, the metabolic phenotype of
the failing heart appears to be at least in part dependent on the stage/
severity of the syndrome; however, the metabolic alterations are not
clear cut. In ventricular homogenates obtained from hearts subjected
to pressure overload with preserved ejection fraction, the rates of
fatty acid β-oxidation are similar to homogenates obtained from
normal hearts, whereas the rates of glycolysis are accelerated [143].
Furthermore, fatty acid β-oxidation rates are also similar in
ventricular homogenates obtained from hearts subjected to myocar-
dial infarction and subsequent heart failure at a time point when there
is a downregulation in genes encoding enzymes involved in fatty acid
oxidation including acyl-CoA synthase and CPTI [144]. These ﬁndings
are also extrapolated to the whole heart, where fatty acid β-oxidation
does not differ in acute heart failure secondary to aortic banding in
rats [145], or in the canine microembolization model, where glucose
uptake and oxidation are also preserved relative to the normal heart
[146].
Previous studies indicate that despite decreased fatty acid uptake
(likely owing to decreased regional coronary blood ﬂow), cardiac fatty
acid β-oxidation is normal in patients with asymptomatic hypertro-
phic cardiomyopathy [147]. Additionally, a previous report examining
primarily NYHA functional class III patients indicates that fatty acid
utilization is increased secondary to enhanced lipolysis [148]. The
increased fatty acid utilization is also accompanied by elevated
plasma lactate concentrations, indicative of fatty acid-induced
impairments in whole-body carbohydrate oxidation [148]. Interest-
ingly, in clinically stable NYHA functional class II and III patients
cardiac fatty acid uptake [149,150] and fatty acid β-oxidation [149]
were greater than that observed in healthy controls, while glucose
uptake [150] and oxidation were lower [149]. These alterations in
cardiac fatty acid and glucose utilization in NYHA functional class II–IIIpatients may negatively impact cardiac efﬁciency, and may thus
represent a viable therapeutic target tomodulate the balance between
fatty acid and glucose utilization in heart failure.
Recent studies indicate that experimental models of severe end-
stage heart failure are accompanied by a depression in overall
oxidative metabolism. Twenty weeks following pressure overload-
induced heart failure, secondary to transverse aortic constriction in
rats, there is a decrease in mitochondrial state 3 respiration, as well as
a decrease in both fatty acid (i.e. oleate) and glucose oxidation
[151,152]. Interestingly, in these studies the ratio between fatty acid
β-oxidation and glucose oxidation is not altered. This contrasts with
observations in the canine model of severe heart failure induced by
rapid ventricular pacing. In this model, severe heart failure is
accompanied by decreased rates of fatty β-oxidation, and increased
rates of glucose oxidation [153–155]. The increase in glucose
oxidation appears to be paradoxical, as protein expression of PDH is
decreased, while that of its negative regulator, PDK4 is increased
[153]. The decrease in fatty acid β-oxidation in severe heart failure
was accompanied by decreased expression of retinoid X receptor
(PPAR binding partner), and decreased expression of medium chain
acyl-CoA dehydrogenase (MCAD) [154]. The metabolic phenotype
observed in pacing-induced heart failure is reversible, as the rates of
fatty acid β-oxidation increase, while the rates of glucose oxidation
decrease during a recovery phase following discontinuation of rapid-
ventricular pacing [155].
The ﬁndings of decreased fatty acid β-oxidation in experimental
models of severe heart failure are also transferable to the clinical setting,
as the rates of both fatty acid uptake and oxidation are decreased in
patients with dilated cardiomyopathy (ejection fraction ~32%), while
the rates of glucose uptake are increased [156]. Furthermore, in such
patients, there is an inability to increase fatty acid and glucose uptake in
response to pacing stress, which contributes to mechanical inefﬁciency
[156]. Such defects in fatty acid and glucose uptake may suggest a
considerable degree of ineffective substrate utilization under basal
conditions. Energy substrate supply is also a critical determinant of
cardiac performance and efﬁciency in patients with heart failure.
Marked and acute reductions in circulating fatty acid levels in response
to acipimox (an inhibitor of lipolysis) treatment are accompanied by
large reductions in fatty acid uptake, and decreased cardiac efﬁciency,
although fractional fatty acid β-oxidation remains unchanged [157].
These results indicate that FFAs are an important energy substrate in the
failingheart, and are in linewith the previous suggestion that, “the heart
functions best when it oxidizes two substrates simultaneously [158].”
Alternatively, these ﬁndings also lend support to previous observations
demonstrating that pharmacologically targeting the balance between
fatty acid β-oxidation and glucose oxidation as opposed to markedly
limiting FFA availabilitymay be a viable therapeutic strategy to improve
cardiac efﬁciency in these patients (see Section 6).
5.3. Elevated sympathetic nervous activity, elevated plasma fatty acids,
and insulin resistance in heart failure
Activation of cardiac β-adrenoceptors represents one of the most
powerful physiological inputs to acutely enhance cardiac perfor-
mance. Thus, in an attempt to preserve cardiac output, heart failure
(in particular, systolic heart failure) is often accompanied by
hyperactivity of the sympathetic neuro-humoral axis (see for review
[15,16]). For the purposes of this section, we will only deal with the
neuronal limb of the sympathetic nervous system and its contribution
to elevated plasma fatty acid levels during heart failure. However, it
should be noted that the participation of the humoral limb and the
renin–angiotensin–aldosterone system is equally important
[159,160]. Elevated sympathetic nervous system activity in heart
failure is associated with increased circulating NE levels, plasma
spillover of NE from activated sympathetic nerve ﬁbers, and increased
central sympathetic outﬂow [161]. In untreated heart failure patients,
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healthy individuals following intense exercise [162].
β-adrenoceptor antagonists, which are a mainstay therapy in the
treatment of a number of cardiovascular diseases ranging from angina
to heart failure, act via oxygen-sparing mechanisms linked to a
reduction in cardiac energy demand. In the setting of heart failure,
treatment with β-adrenoceptor antagonists is associated with im-
proved left ventricular performance, reversal of adverse left ventric-
ular remodeling, reduced hospitalization, and ultimately, enhanced
patient survival [16]. Mechanisms involved in the protective beneﬁts
of β-adrenoceptor antagonists in the treatment of heart failure
include: 1) inhibition of the cardiotoxic effects of excessive catechol-
amine discharge, 2) upregulation of β1-adrenoceptors, 3) improve-
ment in subendocardial coronary ﬂow, 4) attenuation of pro-
apoptotic, growth promoting, and vasoconstrictive pathways, 5)
restoration of reﬂex control, and 6) improvedmyocardial performance
due to reduced cardiac energy demand and oxygen consumption.
Reductions in cardiac energy demand and oxygen consumption
have important implications with regards to fatty acid metabolism in
the failing heart, as the consequences of increased sympathetic
nervous system activity in heart failure are important contributing
factors towards its metabolic phenotype. Excess circulating NE levels
will result in elevated rates of adipose tissue lipolysis, which will
subsequently increase the delivery of circulating FFAs to the heart.
Presumably, by reducing neuro-humoral hyperactivity, β-adrenocep-
tor antagonists can reduce catecholamine-induced lipolysis and
therefore decrease circulating plasma FFA levels. Indeed, β-adreno-
ceptor antagonists decrease the mobilization of FFAs from adipose
tissue [163], and therefore lower plasma FFA concentrations
[164,165]. Furthermore, sympathetic hyperactivity, reﬂected by
increased circulating levels of catecholamines and FFAs is reduced
by the β-adrenoceptor antagonist propranolol during the course of
myocardial infarction [93]. These effects may decrease the availability
of circulating FFAs for myocardial fatty acid β-oxidation. Indeed, two
small clinical studies suggest β-adrenoceptor antagonists can de-
crease fatty acid uptake and oxidation [166,167], while increasing LV
function in the absence of increased oxygen utilization [168,169].
Second, activation of β1- and β2-adrenoceptors in the heart results in
chronotropic and inotropic effects, which increase the demand on the
heart and subsequent oxygen consumption. Interestingly, β1-adreno-
ceptors are downregulated and NE uptake decreased in the failing
heart [170,171]. Nonetheless, as heart failure patients have elevations
of sympathetic nervous system activity, the availability of circulating
FFAs is increased. Interestingly, increases in cardiac energy demand
brought about by increased cardiac work are associated with elevated
fatty acid oxidation rates [172]. Thus, one would anticipate that this
effect in combination with the enhanced lipolytic effect accompa-
nying sympathetic nervous system activation may negatively affect
the balance between fatty acid β-oxidation and glucose oxidation, and
so lead to impairments in cardiac efﬁciency.
Sympathetic nervous system hyperactivity and excess catechol-
amine release also impair insulin sensitivity, which contributes to
increased circulating FFA levels as well as the development of whole
body insulin resistance [173]. Indeed, clinical studies demonstrate that
decreasing plasma FFA levels attenuates insulin resistance [174].
Furthermore, insulin resistance is an important contributor to, and is
highly prevalent in the pathogenesis of heart failure. Interestingly,
higher proinsulin levels (a surrogatemarker for insulin resistance)were
observed in patients who subsequently developed heart failure versus
control patients 20 years before the actual diagnosis of heart failure
itself [175]. Indeed,wholebody insulin resistance (which largely reﬂects
changes in skeletal muscle insulin-sensitivity) precedes the develop-
ment of heart failure in humans [176,177]. Whether the myocardium
itself is insulin resistant is often a question of debate [178]. However,
studies using 18F-ﬂuoro-2-deoxyglucose (FDG) positron emission
tomography have shown that heart failure patientswith type 2 diabetesdo exhibit myocardial insulin resistance, as indicated by a signiﬁcant
reduction in myocardial FDG uptake [179]. Furthermore, the canine
model of rapid ventricular pacing-induced heart failure is associated
with a robust myocardial insulin resistance, as seen by a complete
absence of insulin-stimulated myocardial glucose uptake following
hyperinsulinemic–euglycemic clamp [180,181].
An important area of concern when interpreting metabolic changes
in heart failure patients with accompanying insulin resistance/type 2
diabetes is the fact that the metabolic phenotypes of each disease state
are extremely complex. In both animal and human studies, myocardial
metabolism in insulin resistance is associated with enhanced fatty acid
oxidation rates, reduced glucose oxidation rates, and depending on the
severity of insulin resistance, either reduced or unchanged glycolytic
rates [78,79,182–189]. In contrast, as the severity of heart failure
increases, fatty acid oxidation rates decrease while glycolytic rates
increase, with no real change in glucose oxidation rates as the heart
adapts a more fetal metabolic phenotype [10,11]. The fact that there is
ongoing debatewith regards to themetabolic changes that take place in
isolation in both the failing heart and the diabetic heart is undoubtedly
compounded by the fact that the patient population often harbors both
of these diseases. Thus, it will be extremely important for future studies
to try and determine the relative contribution each disease state has on
myocardial metabolism, in order to determine the best metabolic
therapeutic approach.
6. Optimizing energy substrate metabolism — a novel therapeutic
intervention in the ischemic and failing heart
Myocardial ischemia is accompanied by elevated plasma FFA
concentrations and a subsequent increase in the supply of FFAs to
heart. Interestingly, in the setting of ischemia, and under conditions of
increased FFA supply, cardiac fatty acid β-oxidation dominates as the
source of residual oxidative metabolism [100,190,191], while glucose
oxidation is depressed [100,191]. Furthermore, during reperfusion fatty
acid β-oxidation also rapidly recovers, leading to an inhibition of
pyruvate dehydrogenase and an increased production of lactate and
protons [63,64,92,105]. Heart failure is also characterized by complex
alterations in oxidative energy substrate metabolism that are amenable
to pharmacological interventions. Optimizing energy substrate metab-
olism by inhibiting fatty acid β-oxidation, while increasing glucose
oxidation (Fig. 3) may provide a means to increase the efﬁciency of ATP
production and utilization in order to restore cardiac efﬁciency and thus
improve function in both the ischemic/reperfused heart and the failing
heart. However, it is important tonote that in the failingheart, the actual
severity of heart failure may determine whether inhibition of fatty acid
oxidation is a viable therapeutic approach, as in the most severe stages
of heart failure mitochondrial function is severely diminished. As such,
theremay be negative consequences associatedwith reducing oxidative
capacity even further [11].
6.1. Targeting the availability of circulating FFAs
Therapeutically decreasing circulating FFA concentration may
represent a viable strategy to decrease the delivery of FFA to the
myocardium, and hence decrease cardiac fatty acid β-oxidation in the
post-ischemic period as well as in heart failure. Interestingly, in heart
failure, a marked reduction/depletion of plasma FFA can acutely and
transiently impair cardiac efﬁciency, suggesting the importance of
fatty acids as an oxidative substrate in this setting [157]. Therefore,
the degree towhich circulating FFA concentration is decreasedmay be
an important factor determining the subsequent effects on cardiac
efﬁciency and function.
6.1.1. Glucose–insulin–potassium therapy
Glucose–insulin–potassium (GIK) therapy has been shown to
increase the rates of glycolysis and also decrease circulating
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decreases infarct size [192] and improves post-ischemic cardiac
function [194]. A number of studies also demonstrate that GIK therapy
is beneﬁcial when administered at reperfusion [192,195,196]. How-
ever, it should be noted that the effects of insulin itself are inﬂuenced
by the level of circulating FFA supplied to the myocardium [197]. A
disproportionate stimulation of glycolysis relative to glucose oxida-
tion can uncouple the two processes, contribute to intracellular
acidosis [92], andmay attenuate the cardioprotective effects of insulin
[197]. Interestingly, there are reports demonstrating a lack of infarct
size reduction in response to GIK treatment [198]. The Diabetic
Patients with Acute Myocardial Infarction (DIGAMI) study [199]
demonstrates a signiﬁcant long term reduction inmortality in diabetic
patients treated with insulin following myocardial infarction. Other
studies including the Estudios Cardiologicos Latinoamerica Collabo-
rative Group Study (ECLA) with thrombolysis and percutaneous
coronary intervention [195], and the Glucose–Insulin–Potassium
Study demonstrate a reduction in mortality, although the beneﬁt is
limited to patients without heart failure [196]. However, a Polish
study failed to show GIK-induced improvements in survival or the
clinical course of acute myocardial infarction [200]. A more recent
Dutch GIK study also showed a potentially higher mortality in the GIK
group [201]. Thus, there is still no clear consensus as to whether GIK
therapy is beneﬁcial in the treatment of myocardial ischemia,
exempliﬁed by acute myocardial infarction.
6.1.2. β-adrenoceptor antagonists
β-adrenoceptor antagonists are used in the setting of ischemic
heart disease and heart failure in part due to their negative inotropic
and chronotropic effects that decrease cardiac workload and elicit
oxygen sparing. β-adrenoceptor antagonists decrease catecholamine-
induced lipolysis and therefore decrease plasma FFA availability and
extraction. As such, propranolol has been shown to reduce the
increased sympathetic activity during the course of myocardial
infarction [93] while carvedilol has been shown to reduce myocardial
FFA uptake by 57% in patients with heart failure [166,167]. These
effects may be attributed, at least in part to the ability of β-
adrenoceptor antagonists to inhibit CPTI activity [202], and promote
glucose oxidation [203], and hence decrease the oxygen costs of ATP
generation. Interestingly, neither mean myocardial uptake of 18F-FDG
nor the rate of glucose utilization increased signiﬁcantly. Metoprolol,
another β-adrenoceptor antagonist, shows no effect on circulating
FFA [204]. Nonetheless, β-adrenoceptor antagonists improve left
ventricular function independent of alterations in cardiac oxygen
consumption [168,169], effects indicative of improved cardiac
efﬁciency.
6.1.3. Peroxisome proliferator activated receptor ligands
Fibrates, which are selective PPARα agonists, decrease circulating
FFAs, primarily by increasing hepatic expression of fatty acid
oxidation enzymes [205], as well as increasing FACS expression
[206]. The decrease in circulating FFA concentration and decreased
cardiac FFA extraction may decrease myocardial fatty acid β-
oxidation, and suggest the possible utility of these compounds in
the treatment of ischemic heart disease. These effects are evident in
models of diet-induced obesity and insulin resistance, as mice
subjected to diet-induced obesity and treatment with fenoﬁbrate
exhibit a signiﬁcant increase in hepatic fatty acid oxidation rates
[184]. Furthermore, this increase in extra-cardiac fatty acid oxidation
is associated with a reduction in circulating triacylglycerol concentra-
tions, likely contributing to the observed reduction inmyocardial fatty
acid oxidation rates and subsequent increase in glucose oxidation
rates, which ultimately resulted in enhanced recovery of post-
ischemic function. In addition, ﬁbrates can also reduce infarct size in
animal models [207] and improve the recovery of post-ischemic
function [208].PPARβ/δ is involved in regulating the expression of genes involved
in cardiac fatty acid metabolism including FACS, the muscle isoforms
of CPTI, long chain acyl-CoA dehydrogenase, and medium-chain acyl-
CoA dehydrogenase [136,209,210]. Furthermore, the PPARβ/δ-medi-
ated increases in the expression of genes involved in fatty acid
metabolism are accompanied by the expected increases in the rates of
myocardial fatty acid utilization, particularly increased rates of fatty
acid β-oxidation [209,211,212]. In cardiac myocytes, PPARβ/δ acti-
vating ligands also prevent the downregulation of: i) genes involved
in fatty acid metabolism and ii) fatty acid β-oxidation in response to
hypertrophic stimuli [211,212]. Furthermore, PPARβ/δ is also involved
in regulating the expression of genes involved in myocardial glucose
metabolism, including GLUT4, and phosphofructokinase, and cardiac
speciﬁc overexpression of PPARβ/δ increases the rates of myocardial
glucose oxidation [137]. These effects may be beneﬁcial in limiting the
attenuation of the rates of oxidative metabolism in the setting of heart
failure; however, this remains to be investigated.
PPARγ is the target of the thiazolidinedione (TZD) class of
antidiabetic drugs. TZDs promote lipid sequestration in adipose
tissue, thereby decreasing ectopic deposition and storage of excess
lipid. Experimental studies have demonstrated a decrease in plasma
triacylglycerol and FFA concentrations with TZD administration.
Myocardial glucose [213] and lactate [214] uptake and oxidation
[215] have also been shown to increase with TZD treatment. This
increase in glucose utilization, at the expense of fatty acid utilization
may potentially improve cardiac efﬁciency. Indeed, TZDs do have
favorable effects on post-ischemic cardiac function [213–216]. These
ﬁndings are also extrapolated to experimental models of diabetes, as
db/db mice treated for 5 weeks with rosiglitazone have decreased
circulating FFA concentrations, which reduce myocardial fatty acid
oxidation rates, and subsequently increase glucose oxidation rates, as
well as cardiac efﬁciency. These beneﬁcial effects improve the
recovery of post-ischemic cardiac function [217]. In contrast, cardiac
speciﬁc overexpression of PPARγ is associated with the development
of cardiomyopathy and disrupted mitochondrial architecture [218].
Furthermore clinical trials investigating the use of TZDs in diabetic
heart failure patients have raised concerns about its safety. Particu-
larly, increased ﬂuid retention and vascular permeability have been
implicated in aggravating heart failure in diabetic patients [219]. The
Prospective Pioglitazone Clinical Trial in Macrovascular Events
(PROactive) Study demonstrated an increased incidence of heart
failure in patients treated with pioglitazone [220]. Recent meta-
analysis of the risk of myocardial infarction and cardiovascular
mortality suggests that rosiglitazone therapy causes an increased
risk ofmyocardial infarction, although no increase in cardiovascular or
all cause mortality was observed [221,222]. However, the post-hoc
analysis of the BARI 2D trial indicated that there was no increase in
myocardial infarction or risk of death from rosiglitazone (Bach et al.
ADA late breaking clinical studies session, 2010). Thus it remains to be
determined whether PPARγ agonists are detrimental in heart failure
and/or ischemic heart disease until the results of Rosiglitazone
Evaluated for Cardiac Outcomes and Regulation of Glycemia in
Diabetes (RECORD) trial are completed.
6.2. Targeting mitochondrial fatty acid uptake
As the rate-limiting enzyme mediating mitochondrial fatty acid
uptake, CPTI is an attractive target for inhibiting myocardial fatty acid
β-oxidation. A number of CPTI inhibitors have been developed,
including etomoxir and perhexiline, both of which have been
demonstrated to have anti-ischemic/oxygen-sparing effects as well
as having beneﬁcial effects in the treatment of heart failure.
6.2.1. Etomoxir
Etomoxir is an irreversible inhibitor of CPTI [223]. The compound
has been shown to improvemyocardial function, concomitant with an
Fig. 3. Targeting fatty acid and glucose oxidation as a therapeutic intervention in ischemic and ischemic/reperfused hearts, and the failing heart. Fatty acid oxidation can be targeted
at different levels for treatment of both ischemic heart disease and heart failure. Circulating fatty acids can be decreased with the use of glucose–insulin–potassium (GIK),
peroxisome proliferator activated receptor (PPAR) agonists and β-adrenoceptor antagonists (1). The mitochondrial uptake of long chain acyl-CoAs can be reduced with the use of
carnitine palmitoyl tranferase-I (CPTI) and malonyl-CoA decarboxylase (MCD) inhibitors (2). Partial fatty acid oxidation inhibitors can inhibit the rates of myocardial fatty acid
oxidation (4). Glucose oxidation can be increased with the use compounds that increase pyruvate dehydrogenase (PDH) complex activity by inhibiting PDK4 (5).
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[224–226] as well as in hearts from diabetic rats [227,228]. Thus
etomoxir possesses anti-ischemic effects and may potentially be
effective in the treatment of diabetic cardiomyopathy. Etomoxir
treatment has also been shown to improve ventricular function in rat
hearts subjected to pressure overload [229], which can progress to
heart failure. Furthermore, etomoxir is suggested to be effective in
treating heart failure by improving the rate of sarcoplasmic reticulum
calcium uptake in the setting of cardiac hypertrophy [230]. However,
results of clinical trials with etomoxir remain inconclusive. The ﬁrst
open-label trial with etomoxir (80 mg daily for 3 months) showed an
improvement in LV ejection fraction, cardiac output at peak exercise,
and clinical status in patients with NYHA class II heart failure [231].
However, a more recent double-blindmulti-centered clinical trial was
prematurely terminated due to unacceptably high liver transaminase
levels in 4 etomoxir-treated patients [232].
6.2.2. Perhexiline
Perhexiline was originally utilized as an anti-anginal agent in the
1970's. However, cases of hepatic failure and neuropathy have led tothe decline of its use. The toxicity is related to phospholipid
accumulation, a direct consequence of CPTI inhibition. However, it
has recently been shown that toxicity can be dramatically reduced by
titrating the plasma concentration of perhexiline to between 150 to
600 ng/mL, which inhibits the cardiac but not hepatic isoform of CPTI.
When added to maximum anti-anginal therapy, with plasma-guided
dose titration, perhexiline decreases the frequency of angina attacks,
while increasing exercise capacity [233]. Perhexiline has also been
demonstrated to be effective in chronic heart failure improving left
ventricular ejection fraction and VO2 max [234], as well as improving
overall cardiac energetics [235]. These beneﬁcial effects suggest that
perhexiline-induced alterations in fatty acid utilization, at the level of
mitochondrial fatty acid uptake are therapeutically relevant in the
treatment of both ischemic heart disease(s) and heart failure.
6.2.3. Malonyl-CoA decarboxylase inhibitors
Inhibitors of MCD activity increase malonyl-CoA content in both
mouse and rat hearts [236,237]. The inhibition of MCD has been
shown to cause an increase in glucose oxidation and insulin sensitivity
in rodents [32]. Administration of speciﬁc MCD inhibitors to working
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glucose oxidation, improved cardiac efﬁciency, and an increase in the
recovery of post-ischemic function [236,238–240]. The ability to alter
the balance between fatty acid β-oxidation and glucose oxidation also
persists in the swine model of demand-induced ischemia [238,239].
Thus pharmacologically increasing malonyl-CoA content, to subse-
quently decrease mitochondrial fatty acid uptake and fatty acid β-
oxidation has salutary effects in the setting of ischemic heart disease
(s). It remains to be determined whether these effects are also
transferable to heart failure.
6.3. Targeting mitochondrial fatty acid β-oxidation
Another approach to inhibit mitochondrial fatty acid oxidation is
to directly inhibit the enzymes of fatty acid β-oxidation. A number of
fatty acid β-oxidation inhibitors have been developed and have been
proven effective against ischemic heart disease and heart failure.
6.3.1. Trimetazidine
Trimetazidine is a partial fatty acid β-oxidation inhibitor that
competitively inhibits long chain 3-ketoacyl-CoA thiolase (KAT)
[241,242]. The inhibition of fatty acid β-oxidation is accompanied by
an increase in glucose oxidation. This would be beneﬁcial in ischemia
as increased glucose oxidation can decrease proton production arising
from the uncoupling of glycolysis from glucose oxidation. Interest-
ingly, trimetazidine has also been shown to lack inhibitory effects on
3-KAT in rat hearts [243]. In the setting of pressure-overload cardiac
hypertrophy (where the rate of fatty acid β-oxidation is already
decreased), trimetazidine has been shown to be cardioprotective
independent of alterations in fatty acid β-oxidation, but rather, via
reductions in glycolysis which subsequently decrease proton produc-
tion [244]. The decrease in proton production improves the coupling
between glycolysis and glucose oxidation, an effect demonstrated to
attenuate acidosis, improve cardiac efﬁciency and cardiac function
[92,245].
Results from clinical studies have conﬁrmed the effectiveness of
trimetazidine as an anti-ischemic agent. Treatment of angina with
trimetazidine has been shown to increase the time to 1-mm ST
segment depression, while decreasing weekly nitrate consumption
[246,247]. Trimetazidine has been shown to have comparable
effectiveness as propranolol in treating stable angina [248]. Combi-
nation therapy with standard anti-anginal therapy has also been
shown to reduce the number of symptomatic episodes of angina and
improve time to ischemia-related ECG changes on exercise testing
[249]. Trimetazidine is also effective in treating heart failure.
Trimetazidine normalizes the PCr/ATP ratio in patients with ischemic
cardiomyopathy [250]. The addition of the drug to treatment
regimens improves NYHA functional class, LV end-diastolic volume
and ejection fraction in patients with heart failure and ischemic
cardiomyopathy [250,251]. Trimetazidine is also effective in the
treatment of non-ischemic/idiopathic heart failure. In patients with
idiopathic dilated cardiomyopathy, trimetazidine has been shown to
improve LV ejection fraction. This improvement coincides with a
decrease in myocardial fatty acid β-oxidation without changes in total
myocardial oxidative rates, implying an increase in glucose utilization
[252]. Interestingly, the improved ejection fraction is accompanied by
a decrease in fatty acid oxidation by only 10% in the failing heart,
suggesting that additional effects may partly be responsible for the
observed beneﬁt. Indeed, an increase in β1-receptor blockade with
the use of trimetazidine has also been indicated, suggesting a
synergistic effect with β-adrenoceptor antagonists [252].
6.3.2. Ranolazine
Ranolazine is a partial fatty acid β-oxidation inhibitor, which
reciprocally increases glucose oxidation [253,254] and PDH activity
[255,256]. The protective effects of ranolazine have been associatedwith the shift from fatty acid β-oxidation to glucose oxidationwithout
a concomitant increase in glycolysis [254] or lactate release [255],
indicative of improved coupling between glycolysis and glucose
oxidation. Besides inhibiting fatty acid β-oxidation, ranolazine has
also been shown to inhibit the electron transport chain in damaged
and uncoupled mitochondria and is postulated to prevent ATP
wasting attributable to futile cycling [257]. Ranolazine can also
directly inhibit the late Na+ current and prevent adverse increases in
diastolic [Ca2+]i attributable to Na+-dependent Ca2+ overload and
thus limit ischemic myocardial injury [258,259]. Recently, it has been
proposed that the inhibition of the late Na+ current is the mechanism
responsible for the cardioprotective effects of ranolazine based on the
apparent lower concentration (≤10 μM) [260] required for Na+
current inhibition versus that required for partial fatty acid oxidation
inhibition (100 μM) [243], as well as the observation that inhibition of
fatty acid β-oxidation by the fatty acid oxidation inhibitor CVT-4325
does not improve left ventricular function in ischemic rat hearts [261].
However, a number of studies have demonstrated improved cardiac
function concomitant with increased glucose oxidation and decreased
fatty acid oxidation at the therapeutic concentration of ≤10 μM
[254,255]. Thus, it is possible that both late Na+ current inhibition and
partial inhibition of fatty acid β-oxidation contribute to the cardio-
protective effects of ranolazine.
In experimental studies, ranolazine has been shown to attenuate
myocardial stunning and reduce infarct size in rabbit hearts [262,263].
In a canine heart failuremodel, ranolazine can acutely increase cardiac
ejection fraction, stroke volume and mechanical efﬁciency without
increasing oxygen consumption [264,265], while 3 months of treat-
ment prevents the progression of LV remodeling and contractile
dysfunction [266]. Clinically, ranolazine has been approved in the
United States for the treatment of chronic stable angina. Ranolazine
monotherapy has been shown to increase exercise capacity and time
to 1-mm ST segment depression [267,268], and to reduce the number
of weekly angina attacks [269]. When added to standard anti-anginal
therapy, ranolazine also confers additional protection [269,270].
Antiarrhythmic effects, attributed to the inhibition of late Na+
current, have also been demonstrated clinically with the use of
ranolazine in patients with non-ST-segment elevation acute coronary
syndromes, showing decreased incidence of ventricular tachycardia,
supraventricular tachycardia, and new onset atrial ﬁbrillation [271].
The anti-ischemic effects and antiarrhythmic effects of ranolazine
appear to occur at similar concentrations and may both contribute to
its cardioprotective efﬁcacy.
6.4. Targeting the pyruvate dehydrogenase complex and glucose
oxidation
6.4.1. Pyruvate dehydrogenase kinase inhibitors
In both ischemic heart disease as well as heart failure, there are
defects in oxidative fatty acid and glucose metabolism. The beneﬁcial
effects of both trimetazidine and ranolazine in the ischemic/
reperfused heart and failing heart suggest that altering the balance
between fatty acid and glucose oxidation, such that it favors glucose
oxidation has salutary effects on cardiac function. Directly increasing
myocardial glucose oxidation represents another approach to im-
prove cardiac function. Dichloroacetate (DCA) stimulates the mito-
chondrial PDH complex via the inhibition of the activity of PDK.
Improved coupling between glycolysis and glucose oxidation con-
tributes to the mechanism(s) by which DCA exerts its cardioprotec-
tive effects [92,245]. Experimental studies show that DCA increases
post-ischemic recovery of cardiac function in neonatal rabbit [272],
rat [105] as well as swine hearts [273]. Furthermore, DCA increases
glucose oxidation rates in hearts obtained from rats treated with
streptozotocin (an experimental model of type 1 diabetes). The
stimulation of glucose oxidation was associated with an improvement
in LV developed pressure [274], however, the DCA-induced increase in
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ischemic function [275].
Clinical data on the use of DCA is scarce. In a small clinical study,
where DCA was given to patients with coronary artery disease via
intravenous infusion, improvements in LV stroke volume was
observed in the absence of changes in heart rate, left ventricular
end diastolic pressure or myocardial oxygen consumption [276].
Furthermore, a recent study indicates that treatment of Dahl salt-
sensitive rats attenuates the transition from left ventricular hyper-
trophy to heart failure, beneﬁcial effects associated with improved
myocardial energetics [277]. A potential advantage with regards to
the use of DCA as opposed to the use of insulin is the selective
stimulation of glucose oxidation in the post-ischemic period
[106,278–282], whereas insulin stimulates both glycolysis and
glucose oxidation. As such, DCA improves the coupling between
glycolysis and glucose oxidation thereby decreasing proton produc-
tion, while insulin can uncouple the two processes leading to an
increase in proton production during reperfusion. These effects may
contribute to the controversial results of trial of GIK therapy [197].
In addition to DCA several other inhibitors of PDK activity have
been developed. The novel PDK inhibitor SDZ048-619 increases PDH
activity in cardiac muscle, skeletal muscle, liver, and kidney in the
diabetic Zucker rat [283,284]. The compound AZD7545 (a selective
PDK2 inhibitor) has been demonstrated to increase PDH activity in
liver (where PDK2 is the predominant isoform) with lesser increases
in cardiac and skeletal muscle [285].Whether or not these compounds
elicit alterations in cardiac glucose oxidation similar to those elicited
by DCA remains to be characterized; nonetheless, these additional
PDK inhibitors may be useful pharmacological tools to further validate
the stimulation of glucose oxidation as a therapeutic target in the
ischemic and failing heart.
6.5. Medium chain fatty acids
Medium chain fatty acids (MCFA) typically possess acyl-chain
lengths of 6–12 carbons, are saturated, and have unique metabolic
properties that differ from those of long chain FFAs [286]. Speciﬁcally,
MCFAs do not require protein-mediated transport to cross the
sarcolemmal or mitochondrial membranes. As such, MCFAs bypass
CPTI and are activated in the mitochondrial matrix by the enzyme
medium chain acyl-CoA synthetase. Owing to these metabolic
properties, MCFAs appear to be preferentially directed towards fatty
acid β-oxidation as opposed to incorporation into triacylglycerol. Such
an effect may have the potential to limit the futile cycling of fatty acids
through the triacylglycerol pool [86], and hence decrease wasteful
ATP hydrolysis (see Section 3.3). Furthermore, MCFAs of odd chain
lengths including 7, and 9 carbons generate the anaplerotic substrate,
propionyl-CoA after 2 or 3 rounds of fatty acid β-oxidation,
respectively. These effects may be of relevance in both the
ischemic–reperfused heart as well as the failing heart.
Despite the ability to increase the myocardial contents of the TCA
cycle intermediates citrate [287], malate [288], and fumarate [288]
MCFAs do not improve the recovery of post-ischemic function
[287,288]. Although the direct effects of MCFAs in the failing heart
have not been examined, several studies have characterized their
effects in the presence of pressure overload cardiac hypertrophy (i.e.
in the spontaneously hypertensive rat model), which can progress to
heart failure. Dietary supplementation with MCFAs corrects hyper-
insulinemia, attenuates cardiac hypertrophy, prevents the rise in LV
diastolic pressure, and limits decrements in contractile function [289–
291]. With respect to energy substrate metabolism, MCFAs prevent
decreases in the expression of MCAD, while attenuating increases in
the expression of PFK-1 in the presence of cardiac hypertrophy [290].
These ﬁndings may suggest that MCFAs are capable of preventing the
downregulation of oxidative metabolism and concomitant shift
towards glycolysis in the hypertrophied heart. Interestingly, in thepresence of cardiac hypertrophy, in response to adrenergic stress
(which commonly accompanies heart failure), the contribution of
exogenous long chain fatty acids (e.g. oleate) to energetic require-
ments decreases, and is not accompanied by a compensatory increase
in carbohydrate oxidation, but rather enhanced lactate release [292],
indicative of an uncoupling between glycolysis and glucose oxidation.
Under these conditions, the MCFA octanoate is readily oxidized, and
does not affect the oxidation of exogenous oleate [292]. Furthermore,
octanoate increases tissue levels of TCA cycle intermediates, partic-
ularly isocitrate and malate [292], again suggesting that MCFAs are a
readily oxidizable substrate that may surmount limited rates of
oxidative metabolism in the hypertrophied heart. Whether MCFAs
can elicit such alterations in oxidative metabolism and improve
function in the failing heart remains to be addressed.
7. Limitations
7.1. Inhibition of fatty acid β-oxidation and lipotoxicity
A potential drawback associated with the inhibition of myocardial
fatty acid oxidation during either ischemic heart disease or heart
failure is that if fatty acids are not oxidized, they can be shuttled and
stored as intra-myocardial triacylglycerol and other lipid intermedi-
ates including diacylglycerol and ceramide [10,293]. It has been
proposed that the accumulation of lipid intermediates such as
ceramide in the myocardium is directly toxic, and may lead to
apoptotic cell death of cardiac myocytes, as well as myocardial
ﬁbrosis, LV chamber expansion, contractile dysfunction, and impaired
diastolic ﬁlling, a collection of events often referred to as “cardiac
lipotoxicity” [11,135,294–300]. Directly stimulating glucose oxidation
with compounds such as DCA (as opposed to inhibiting fatty acid β-
oxidation), may provide a means to circumvent cardiac lipotoxicity.
However, increases in glucose oxidation can result in a secondary
increase in malonyl-CoA content and subsequent inhibition of fatty
acid oxidation via a Randle Cycle effect, thereby resulting in an
accumulation of intra-myocardial triacylglycerol [301]. Although the
general phenomenon of cardiac lipotoxicity has been observed in a
number of genetic models in rodents, it remains poorly deﬁned and
continues to lack a clinically equivalent condition. Interestingly,
several studies have now demonstrated dissociation between myo-
cardial lipid accumulation and cardiac function, thereby suggesting
that an increase in intra-myocardial triacylglycerol content does not
necessarily equate to decreased contractile function [189,302].
7.2. Energy substrate metabolism in the isolated working heart
preparation
The majority of studies assessing in vitro cardiac function and
metabolism utilize the isolated working heart preparation. The
isolated working heart preparation is an ideal experimental model
for the simultaneous measurement of various indices of cardiac
function and energy substrate metabolism. A major factor controlling
ﬂux through the pathways of fatty acid β-oxidation, glycolysis,
glucose oxidation, and the tricarboxylic acid cycle is external work
performed by the heart. The ability to perfuse the isolated heart at
selected preload and afterload pressures, as well as with both glucose
and fatty acids allows the characterization of cardiac substrate
metabolism at relevant workloads as well as over a range of
workloads, in either a physiological or pathological setting (e.g.
failing heart). However, it must be noted that the majority of ﬁndings
utilizing this experimental model, represent left ventricular function
and left ventricular metabolism. As there is an absence of right
ventricular load, the contribution(s) of right ventricular function and
metabolism to overall cardiac function is (are) not apparent or
assessed.
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Cardiac fatty acid and glucosemetabolism, speciﬁcally fatty acid β-
oxidation and glucose oxidation, are highly regulated processes that
meet the majority of myocardial energetic requirements. The balance
between fatty acid β-oxidation and glucose oxidation is an important
determinant of cardiac efﬁciency, and function. Cardiac ischemia,
ischemia/reperfusion, and heart failure are characterized by complex
alterations in fatty acid and glucose oxidation that ultimately have a
negative impact on cardiac efﬁciency and function. Pharmacologically
shifting the balance between fatty acid β-oxidation and glucose
oxidation by targeting either i) the cellular uptake of energy
substrates, ii) transcriptional regulators of energy substrate metabo-
lism, iii) mitochondrial fatty acid uptake, iv) mitochondrial fatty acid
β-oxidation, and v) glucose oxidation such that glucose oxidation is
increased at the expense of fatty acid oxidation can improve the
efﬁciency of ATP generation and hydrolysis. Such alterations in energy
substrate metabolism can limit the deﬁcits in cardiac efﬁciency and
function that occur during cardiac ischemia and heart failure.
Acknowledgements
This work was supported by grants from the Canadian Institutes of
Health Research and the Canadian Diabetes Association to GDL. GDL is
an Alberta Heritage Foundation for Medical Research (AHFMR)
Scientist. WK is supported by fellowship awards from the Heart and
Stroke Foundation of Canada and AHFMR. WW is supported by a
fellowship award from AHFMR. JRU is supported by fellowship awards
from AHFMR and the Canadian Institutes of Health Research.
References
[1] J.M. Neely, H.E. Morgan, Relationship between carbohydrate metabolism and
energy balance of heart muscle, Annu. Rev. Physiol 36 (1974) 413–459.
[2] S. Neubauer, The failing heart—an engine out of fuel, N. Engl. J. Med. 356 (2007)
1140–1151.
[3] R.J. Bing, A. Siegel, I. Ungar, M. Gilbert, Metabolism of the human heart. II. Studies
on fat, ketone and amino acid metabolism, Am. J. Med. 16 (1954) 504–515.
[4] L.H. Opie, Metabolism of the heart in health and disease. I, Am. Heart J. 76 (1968)
685–698.
[5] L.H. Opie, Metabolism of the heart in health and disease. II, Am. Heart J. 77 (1969)
100–122.
[6] J.V. Messer, W.A. Neill, The oxygen supply of the human heart, Am. J. Cardiol. 9
(1962) 384–394.
[7] J.V. Messer, R.J. Wagman, H.J. Levine, W.A. Neill, N. Krasnow, R. Gorlin, Patterns of
human myocardial oxygen extraction during rest and exercise, J. Clin. Invest. 41
(1962) 725–742.
[8] E.S. Ford, U.A. Ajani, J.B. Croft, J.A. Critchley, D.R. Labarthe, T.E. Kottke, W.H. Giles,
S. Capewell, Explaining the decrease in U.S. deaths from coronary disease, 1980–
2000, N. Engl. J. Med. 356 (2007) 2388–2398.
[9] E.S. Ford, S. Capewell, Coronary heart disease mortality among young adults in
the U.S. from 1980 through 2002: concealed leveling of mortality rates, J. Am.
Coll. Cardiol. 50 (2007) (1980) 2128–2132.
[10] G.D. Lopaschuk, J.R. Ussher, C.D. Folmes, J.S. Jaswal, W.C. Stanley, Myocardial
fatty acid metabolism in health and disease, Physiol. Rev. 90 (2010) 207–258.
[11] W.C. Stanley, F.A. Recchia, G.D. Lopaschuk, Myocardial substrate metabolism in
the normal and failing heart, Physiol. Rev. 85 (2005) 1093–1129.
[12] S.A. Hunt, W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, T.G. Ganiats, M.
Jessup, M.A. Konstam, D.M. Mancini, K. Michl, J.A. Oates, P.S. Rahko, M.A. Silver, L.W.
Stevenson,C.W.Yancy, F. AmericanCollegeofCardiology,A.AmericanHeart, Focused
update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and
management of heart failure in adults. A report of theAmericanCollege of Cardiology
Foundation/AmericanHeartAssociationTask Force onPracticeGuidelinesdeveloped
in collaboration with the International Society for Heart and Lung Transplantation,
J. Am. Coll. Cardiol. 53 (2009) (2009) e1–e90.
[13] P.N. Peterson, J.S. Rumsfeld, L. Liang, A.F. Hernandez, E.D. Peterson, G.C. Fonarow,
F.A. Masoudi, American Heart Association GetWith The Guidelines-Heart Failure
Program, Treatment and risk in heart failure: gaps in evidence or quality? Circ.
Cardiovasc. Qual. Outcomes 3 (2010) 309–315.
[14] J.J. McMurray, M.A. Pfeffer, Heart failure, Lancet 365 (2005) 1877–1889.
[15] L.H. Opie, J. Knuuti, The adrenergic-fatty acid load in heart failure, J. Am. Coll.
Cardiol. 54 (2009) 1637–1646.
[16] F. Triposkiadis, G. Karayannis, G. Giamouzis, J. Skoularigis, G. Louridas, J. Butler,
The sympathetic nervous system in heart failure physiology, pathophysiology,
and clinical implications, J. Am. Coll. Cardiol. 54 (2009) 1747–1762.[17] M.S. Murthy, S.V. Pande, Mechanism of carnitine acylcarnitine translocase-
catalyzed import of acylcarnitines into mitochondria, J. Biol. Chem. 259 (1984)
9082–9089.
[18] M.S. Murthy, S.V. Pande, Some differences in the properties of carnitine
palmitoyltransferase activities of the mitochondrial outer and inner membranes,
Biochem. J. 248 (1987) 727–733.
[19] M.S. Murthy, S.V. Pande, Malonyl-CoA binding site and the overt carnitine
palmitoyltransferase activity reside on the opposite sides of the outer
mitochondrial membrane, Proc. Natl Acad. Sci. USA 84 (1987) 378–382.
[20] W.C. Stanley, M.P. Chandler, Energy metabolism in the normal and failing heart:
potential for therapeutic interventions, Heart Fail. Rev. 7 (2002) 115–130.
[21] A.A. Wolff, H.H. Rotmensch, W.C. Stanley, R. Ferrari, Metabolic approaches to the
treatment of ischemic heart disease: the clinicians' perspective, Heart Fail. Rev. 7
(2002) 187–203.
[22] J.D. McGarry, N.F. Brown, The mitochondrial carnitine palmitoyltransferase
system. From concept to molecular analysis, Eur. J. Biochem. 244 (1997) 1–14.
[23] H. Schulz, Oxidation of Fatty Acids in Eukaryotes, 5 ed.Elsevier B.V., Amsterdam,
2007.
[24] J.R. Dyck, G.D. Lopaschuk, Malonyl CoA control of fatty acid oxidation in the
ischemic heart, J. Mol. Cell. Cardiol. 34 (2002) 1099–1109.
[25] N. Kudo, A.J. Barr, R.L. Barr, S. Desai, G.D. Lopaschuk, High rates of fatty acid
oxidation during reperfusion of ischemic hearts are associated with a decrease in
malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase
inhibition of acetyl-CoA carboxylase, J. Biol. Chem. 270 (1995) 17513–17520.
[26] K.N. Frayn, P. Arner, H. Yki-Jarvinen, Fatty acid metabolism in adipose tissue,
muscle and liver in health and disease, Essays Biochem. 42 (2006) 89–103.
[27] P.J. Randle, Regulatory interactions between lipids and carbohydrates: the
glucose fatty acid cycle after 35 years, Diab. Metab. Rev. 14 (1998) 263–283.
[28] P.J. Randle, P.B. Garland, C.N. Hales, E.A. Newsholme, The glucose fatty-acid cycle.
Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus,
Lancet 1 (1963) 785–789.
[29] C.D. Folmes, G.D. Lopaschuk, Role of malonyl-CoA in heart disease and the
hypothalamic control of obesity, Cardiovasc. Res. 73 (2007) 278–287.
[30] J.R. Ussher, G.D. Lopaschuk, The malonyl CoA axis as a potential target for
treating ischaemic heart disease, Cardiovasc. Res. 79 (2008) 259–268.
[31] J.R. Ussher, G.D. Lopaschuk, Targeting malonyl CoA inhibition of mitochondrial
fatty acid uptake as an approach to treat cardiac ischemia/reperfusion, Basic Res.
Cardiol. 104 (2009) 203–210.
[32] D.G. Hardie, Regulation of fatty acid synthesis via phosphorylation of acetyl-CoA
carboxylase, Prog. Lipid Res. 28 (1989) 117–146.
[33] D.G. Hardie, Regulation of fatty acid and cholesterol metabolism by the AMP-
activated protein kinase, Biochim. Biophys. Acta 1123 (1992) 231–238.
[34] D.G. Hardie, An emerging role for protein kinases: the response to nutritional
and environmental stress, Cell. Signal. 6 (1994) 813–821.
[35] S.A. Hawley, M. Davison, A. Woods, S.P. Davies, R.K. Beri, D. Carling, D.G. Hardie,
Characterization of the AMP-activated protein kinase kinase from rat liver and
identiﬁcation of threonine 172 as themajor site at which it phosphorylates AMP-
activated protein kinase, J. Biol. Chem. 271 (1996) 27879–27887.
[36] D. Carling, K. Aguan, A. Woods, A.J. Verhoeven, R.K. Beri, C.H. Brennan, C.
Sidebottom, M.D. Davison, J. Scott, Mammalian AMP-activated protein kinase is
homologous to yeast and plant protein kinases involved in the regulation of
carbon metabolism, J. Biol. Chem. 269 (1994) 11442–11448.
[37] J.R. Dyck, G. Gao, J. Widmer, D. Stapleton, C.S. Fernandez, B.E. Kemp, L.A. Witters,
Regulation of 5′-AMP-activated protein kinase activity by the noncatalytic beta
and gamma subunits, J. Biol. Chem. 271 (1996) 17798–17803.
[38] J. Gao, L. Waber, M.J. Bennett, K.M. Gibson, J.C. Cohen, Cloning and mutational
analysis of human malonyl-coenzyme A decarboxylase, J. Lipid Res. 40 (1999)
178–182.
[39] D. Stapleton, E. Woollatt, K.I. Mitchelhill, J.K. Nicholl, C.S. Fernandez, B.J. Michell,
L.A. Witters, D.A. Power, G.R. Sutherland, B.E. Kemp, AMP-activated protein
kinase isoenzyme family: subunit structure and chromosomal location, FEBS
Lett. 409 (1997) 452–456.
[40] J. Weekes, S.A. Hawley, J. Corton, D. Shugar, D.G. Hardie, Activation of rat liver
AMP-activated protein kinase by kinase kinase in a puriﬁed, reconstituted
system. Effects of AMP and AMP analogues, Eur. J. Biochem. 219 (1994)
751–757.
[41] A.E. Reszko, T. Kasumov, F. David, K.R. Thomas, K.A. Jobbins, J.F. Cheng, G.D.
Lopaschuk, J.R. Dyck, M. Diaz, C. Des Rosiers, W.C. Stanley, H. Brunengraber,
Regulation of malonyl-CoA concentration and turnover in the normal heart, J.
Biol. Chem. 279 (2004) 34298–34301.
[42] M.R. Munday, Regulation of mammalian acetyl-CoA carboxylase, Biochem. Soc.
Trans. 30 (2002) 1059–1064.
[43] B. Comte, G. Vincent, B. Bouchard, M. Jette, S. Cordeau, C.D. Rosiers, A 13C mass
isotopomer study of anaplerotic pyruvate carboxylation in perfused rat hearts, J.
Biol. Chem. 272 (1997) 26125–26131.
[44] M. Poirier, G. Vincent, A.E. Reszko, B. Bouchard, J.K. Kelleher, H. Brunengraber, C.
Des Rosiers, Probing the link between citrate and malonyl-CoA in perfused rat
hearts, Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H1379–H1386.
[45] D.J. Paulson, K.M. Ward, A.L. Shug, Malonyl CoA inhibition of carnitine
palmityltransferase in rat heart mitochondria, FEBS Lett. 176 (1984) 381–384.
[46] E.D. Saggerson, Carnitine acyltransferase activities in rat liver and heart
measured with palmitoyl-CoA and octanoyl-CoA. Latency, effects of K+, bivalent
metal ions and malonyl-CoA, Biochem. J. 202 (1982) 397–405.
[47] J.D. McGarry, G.F. Leatherman, D.W. Foster, Carnitine palmitoyltransferase I. The
site of inhibition of hepatic fatty acid oxidation by malonyl-CoA, J. Biol. Chem.
253 (1978) 4128–4136.
1346 J.S. Jaswal et al. / Biochimica et Biophysica Acta 1813 (2011) 1333–1350[48] C. Becker, L. Sevilla, E. Tomas, M. Palacin, A. Zorzano, Y. Fischer, The endosomal
compartment is an insulin-sensitive recruitment site for GLUT4 and GLUT1
glucose transporters in cardiac myocytes, Endocrinology 142 (2001)
5267–5276.
[49] C. Postic, A. Leturque, R.L. Printz, P. Maulard, M. Loizeau, D.K. Granner, J. Girard,
Development and regulation of glucose transporter and hexokinase expression
in rat, Am. J. Physiol. 266 (1994) E548–E559.
[50] T. Santalucia, M. Camps, A. Castello, P. Munoz, A. Nuel, X. Testar, M. Palacin, A.
Zorzano, Developmental regulation of GLUT-1 (erythroid/Hep G2) and GLUT-4
(muscle/fat) glucose transporter expression in rat heart, skeletal muscle, and
brown adipose tissue, Endocrinology 130 (1992) 837–846.
[51] C. Depre, M.H. Rider, L. Hue, Mechanisms of control of heart glycolysis, Eur. J.
Biochem. 258 (1998) 277–290.
[52] L.M. King, L.H. Opie, Glucose and glycogen utilisation in myocardial ischemia—
changes in metabolism and consequences for the myocyte, Mol. Cell. Biochem.
180 (1998) 3–26.
[53] R.C. Poole, A.P. Halestrap, Transport of lactate and other monocarboxylates
across mammalian plasma membranes, Am. J. Physiol. 264 (1993) C761–C782.
[54] A.R. Panchal, B. Comte, H. Huang, B. Dudar, B. Roth, M. Chandler, C. Des Rosiers, H.
Brunengraber, W.C. Stanley, Acute hibernation decreases myocardial pyruvate
carboxylation and citrate release, Am. J. Physiol. Heart Circ. Physiol. 281 (2001)
H1613–H1620.
[55] A.R. Panchal, B. Comte, H. Huang, T. Kerwin, A. Darvish, C. des Rosiers, H.
Brunengraber, W.C. Stanley, Partitioning of pyruvate between oxidation and
anaplerosis in swine hearts, Am. J. Physiol. Heart Circ. Physiol. 279 (2000)
H2390–H2398.
[56] K.M. Pound, N. Sorokina, K. Ballal, D.A. Berkich, M. Fasano, K.F. Lanoue, H.
Taegtmeyer, J.M. O'Donnell, E.D. Lewandowski, Substrate–enzyme competition
attenuates upregulated anaplerotic ﬂux through malic enzyme in hypertrophied
rat heart and restores triacylglyceride content: attenuating upregulated
anaplerosis in hypertrophy, Circ. Res. 104 (2009) 805–812.
[57] M.C. Sugden, M.J. Holness, Recent advances in mechanisms regulating glucose
oxidation at the level of the pyruvate dehydrogenase complex by PDKs, Am. J.
Physiol. Endocrinol. Metab. 284 (2003) E855–E862.
[58] E. Kolobova, A. Tuganova, I. Boulatnikov, K.M. Popov, Regulation of pyruvate
dehydrogenase activity through phosphorylation at multiple sites, Biochem. J.
358 (2001) 69–77.
[59] L.G. Korotchkina, M.S. Patel, Site speciﬁcity of four pyruvate dehydrogenase
kinase isoenzymes toward the three phosphorylation sites of human pyruvate
dehydrogenase, J. Biol. Chem. 276 (2001) 37223–37229.
[60] M.J. Holness, M.C. Sugden, Regulation of pyruvate dehydrogenase complex
activity by reversible phosphorylation, Biochem. Soc. Trans. 31 (2003)
1143–1151.
[61] L.L. Spriet, G.J. Heigenhauser, Regulation of pyruvate dehydrogenase (PDH)
activity in human skeletal muscle during exercise, Exerc. Sport Sci. Rev. 30
(2002) 91–95.
[62] A.P. Halestrap, R.C. Poole, S.L. Cranmer, Mechanisms and regulation of lactate,
pyruvate and ketone body transport across the plasma membrane of
mammalian cells and their metabolic consequences, Biochem. Soc. Trans. 18
(1990) 1132–1135.
[63] S.C. Dennis, W. Gevers, L.H. Opie, Protons in ischemia: where do they come from;
where do they go to? J. Mol. Cell. Cardiol. 23 (1991) 1077–1086.
[64] R.A. Robergs, F. Ghiasvand, D. Parker, Biochemistry of exercise-induced
metabolic acidosis, Am. J. Physiol. Regul. Integr. Comp. Physiol. 287 (2004)
R502–R516.
[65] W. Lysiak, P.P. Toth, C.H. Suelter, L.L. Bieber, Quantitation of the efﬂux of
acylcarnitines from rat heart, brain, and liver mitochondria, J. Biol. Chem. 261
(1986) 13698–13703.
[66] R.J. Bing, M.M. Hammond, J.C. Handelsman, R.S. Powers, F. Spencer, J.E.
Eckenhoff, W.T. Goodale, J. Hafkenschiel, S.S. Ketty, The measurement of
coronary blood ﬂow, oxygen consumption, and efﬁciency of the left ventricle
in man, Am. Heart J. 38 (1949) 1–24.
[67] H. Suga, Cardiac energetics: from E(max) to pressure–volume area, Clin. Exp.
Pharmacol. Physiol. 30 (2003) 580–585.
[68] H. Suga, Ventricular energetics, Physiol. Rev. 70 (1990) 247–277.
[69] J.S. Jaswal, J.R. Ussher, G.D. Lopaschuk, Myocardial fatty acid utilization as a
determinant of cardiac efﬁciency and function, Future Lipidol. 4 (2009) 379–389.
[70] P.C. Hinkle, P/O ratios of mitochondrial oxidative phosphorylation, Biochim.
Biophys. Acta 1706 (2005) 1–11.
[71] B. Kadenbach, Intrinsic and extrinsic uncoupling of oxidative phosphorylation,
Biochim. Biophys. Acta 1604 (2003) 77–94.
[72] E.A. Boehm, B.E. Jones, G.K. Radda, R.L. Veech, K. Clarke, Increased uncoupling
proteins and decreased efﬁciency in palmitate-perfused hyperthyroid rat heart,
Am. J. Physiol. Heart Circ. Physiol. 280 (2001) H977–H983.
[73] S. Hidaka, T. Kakuma, H. Yoshimatsu, H. Sakino, S. Fukuchi, T. Sakata,
Streptozotocin treatment upregulates uncoupling protein 3 expression in the
rat heart, Diabetes 48 (1999) 430–435.
[74] A.J. Murray, R.E. Anderson, G.C. Watson, G.K. Radda, K. Clarke, Uncoupling
proteins in human heart, Lancet 364 (2004) 1786–1788.
[75] A.J. Murray, M.A. Cole, C.A. Lygate, C.A. Carr, D.J. Stuckey, S.E. Little, S. Neubauer,
K. Clarke, Increased mitochondrial uncoupling proteins, respiratory uncoupling
and decreased efﬁciency in the chronically infarcted rat heart, J. Mol. Cell.
Cardiol. 44 (2008) 694–700.
[76] S. Boudina, S. Sena, B.T. O'Neill, P. Tathireddy, M.E. Young, E.D. Abel, Reduced
mitochondrial oxidative capacity and increased mitochondrial uncoupling
impair myocardial energetics in obesity, Circulation 112 (2005) 2686–2695.[77] S. Boudina, S. Sena, H. Theobald, X. Sheng, J.J. Wright, X.X. Hu, S. Aziz, J.I. Johnson,
H. Bugger, V.G. Zaha, E.D. Abel, Mitochondrial energetics in the heart in obesity-
related diabetes: direct evidence for increased uncoupled respiration and
activation of uncoupling proteins, Diabetes 56 (2007) 2457–2466.
[78] A.D. Hafstad, A.M. Khalid, O.J. How, T.S. Larsen, E. Aasum, Glucose and insulin
improve cardiac efﬁciency and postischemic functional recovery in perfused
hearts from type 2 diabetic (db/db) mice, Am. J. Physiol. Endocrinol. Metab. 292
(2007) E1288–E1294.
[79] O.J. How, E. Aasum, D.L. Severson, W.Y. Chan, M.F. Essop, T.S. Larsen, Increased
myocardial oxygen consumption reduces cardiac efﬁciency in diabetic mice,
Diabetes 55 (2006) 466–473.
[80] P.K. Mazumder, B.T. O'Neill, M.W. Roberts, J. Buchanan, U.J. Yun, R.C. Cooksey, S.
Boudina, E.D. Abel, Impaired cardiac efﬁciency and increased fatty acid oxidation
in insulin-resistant ob/ob mouse hearts, Diabetes 53 (2004) 2366–2374.
[81] E.L. Seifert, V. Bezaire, C. Estey, M.E. Harper, Essential role for uncoupling
protein-3 inmitochondrial adaptation to fasting but not in fatty acid oxidation or
fatty acid anion export, J. Biol. Chem. 283 (2008) 25124–25131.
[82] M.C. Hunt, S.E. Alexson, The role Acyl-CoA thioesterases play in mediating
intracellular lipid metabolism, Prog. Lipid Res. 41 (2002) 99–130.
[83] J. Himms-Hagen, M.E. Harper, Physiological role of UCP3 may be export of fatty
acids from mitochondria when fatty acid oxidation predominates: an hypoth-
esis, Exp. Biol. Med. (Maywood) 226 (2001) 78–84.
[84] M. Saddik, G.D. Lopaschuk, Myocardial triglyceride turnover and contribution to
energy substrate utilization in isolated working rat hearts, J. Biol. Chem. 266
(1991) 8162–8170.
[85] M. Saddik, G.D. Lopaschuk, Myocardial triglyceride turnover during reperfusion
of isolated rat hearts subjected to a transient period of global ischemia, J. Biol.
Chem. 267 (1992) 3825–3831.
[86] T. Myrmel, K. Forsdahl, T.S. Larsen, Triacylglycerol metabolism in hypoxic,
glucose-deprived rat cardiomyocytes, J. Mol. Cell. Cardiol. 24 (1992) 855–868.
[87] C. Depre, M.H. Rider, K. Veitch, L. Hue, Role of fructose 2, 6-bisphosphate in the
control of heart glycolysis, J. Biol. Chem. 268 (1993) 13274–13279.
[88] D.M. Bers, W.H. Barry, S. Despa, Intracellular Na+ regulation in cardiac
myocytes, Cardiovasc. Res. 57 (2003) 897–912.
[89] L.C. Hool, What cardiologists should know about calcium ion channels and their
regulation by reactive oxygen species, Heart Lung Circ. 16 (2007) 361–372.
[90] B.A. Finegan, G.D. Lopaschuk, C.S. Coulson, A.S. Clanachan, Adenosine alters
glucose use during ischemia and reperfusion in isolated rat hearts, Circulation 87
(1993) 900–908.
[91] B.A. Finegan, G.D. Lopaschuk, M. Gandhi, A.S. Clanachan, Inhibition of glycolysis
and enhanced mechanical function of working rat hearts as a result of adenosine
A1 receptor stimulation during reperfusion following ischaemia, Br. J. Pharma-
col. 118 (1996) 355–363.
[92] Q. Liu, J.C. Docherty, J.C. Rendell, A.S. Clanachan, G.D. Lopaschuk, High levels of
fatty acids delay the recovery of intracellular pH and cardiac efﬁciency in post-
ischemic hearts by inhibiting glucose oxidation, J. Am. Coll. Cardiol. 39 (2002)
718–725.
[93] H.S. Mueller, S.M. Ayres, Propranolol decreases sympathetic nervous activity
reﬂected by plasma catecholamines during evolution of myocardial infarction in
man, J. Clin. Invest. 65 (1980) 338–346.
[94] R.P. Robertson, D. Porte Jr., Adrenergic modulation of basal insulin secretion in
man, Diabetes 22 (1973) 1–8.
[95] R.L. Lerner, D. Porte Jr., Epinephrine: selective inhibition of the acute insulin
response to glucose, J. Clin. Invest. 50 (1971) 2453–2457.
[96] N.J. Christensen, J. Videbaek, Plasma catecholamines and carbohydrate metab-
olism in patients with acute myocardial infarction, J. Clin. Invest. 54 (1974)
278–286.
[97] R.A. Rizza, L.J. Mandarino, J.E. Gerich, Cortisol-induced insulin resistance in man:
impaired suppression of glucose production and stimulation of glucose
utilization due to a postreceptor defect of insulin action, J. Clin. Endocrinol.
Metab. 54 (1982) 131–138.
[98] A.J. Liedtke, S.H. Nellis, O.D. Mjos, Effects of reducing fatty acid metabolism on
mechanical function in regionally ischemic hearts, Am. J. Physiol. 247 (1984)
H387–H394.
[99] S.G. Lloyd, P. Wang, H. Zeng, J.C. Chatham, Impact of low-ﬂow ischemia on
substrate oxidation and glycolysis in the isolated perfused rat heart, Am. J.
Physiol. Heart Circ. Physiol. 287 (2004) H351–H362.
[100] C.D. Folmes, D. Sowah, A.S. Clanachan, G.D. Lopaschuk, High rates of residual
fatty acid oxidation during mild ischemia decrease cardiac work and efﬁciency, J.
Mol. Cell. Cardiol. 47 (2009) 142–148.
[101] J.T. Whitmer, J.A. Idell-Wenger, M.J. Rovetto, J.R. Neely, Control of fatty acid
metabolism in ischemic and hypoxic hearts, J. Biol. Chem. 253 (1978)
4305–4309.
[102] J.R. Neely, D. Feuvray, Metabolic products andmyocardial ischemia, Am. J. Pathol.
102 (1981) 282–291.
[103] J.A. Idell-Wenger, L.W. Grotyohann, J.R. Neely, Coenzyme A and carnitine
distribution in normal and ischemic hearts, J. Biol. Chem. 253 (1978) 4310–4318.
[104] R.B. Jennings, K.A. Reimer, The cell biology of acute myocardial ischemia, Annu.
Rev. Med. 42 (1991) 225–246.
[105] J.J. McVeigh, G.D. Lopaschuk, Dichloroacetate stimulation of glucose oxidation
improves recovery of ischemic rat hearts, Am. J. Physiol. 259 (1990)
H1079–H1085.
[106] M. Taniguchi, C. Wilson, C.A. Hunter, D.J. Pehowich, A.S. Clanachan, G.D.
Lopaschuk, Dichloroacetate improves cardiac efﬁciency after ischemia indepen-
dent of changes in mitochondrial proton leak, Am. J. Physiol. Heart Circ. Physiol.
280 (2001) H1762–H1769.
1347J.S. Jaswal et al. / Biochimica et Biophysica Acta 1813 (2011) 1333–1350[107] G.T. Rowe, N.H. Manson, M. Caplan, M.L. Hess, Hydrogen peroxide and hydroxyl
radical mediation of activated leukocyte depression of cardiac sarcoplasmic
reticulum. Participation of the cyclooxygenase pathway, Circ. Res. 53 (1983)
584–591.
[108] R. Klocke, W. Tian, M.T. Kuhlmann, S. Nikol, Surgical animal models of heart
failure related to coronary heart disease, Cardiovasc. Res. 74 (2007) 29–38.
[109] E. Monnet, J.C. Chachques, Animal models of heart failure: what is new? Ann.
Thorac. Surg. 79 (2005) 1445–1453.
[110] M. Beer, T. Seyfarth, J. Sandstede, W. Landschutz, C. Lipke, H. Kostler, M. von
Kienlin, K. Harre, D. Hahn, S. Neubauer, Absolute concentrations of high-energy
phosphate metabolites in normal, hypertrophied, and failing human myocardi-
um measured noninvasively with (31)P-SLOOP magnetic resonance spectros-
copy, J. Am. Coll. Cardiol. 40 (2002) 1267–1274.
[111] M.A. Conway, J. Allis, R. Ouwerkerk, T. Niioka, B. Rajagopalan, G.K. Radda,
Detection of low phosphocreatine to ATP ratio in failing hypertrophied human
myocardium by 31P magnetic resonance spectroscopy, Lancet 338 (1991)
973–976.
[112] L. Nascimben, J. Friedrich, R. Liao, P. Pauletto, A.C. Pessina, J.S. Ingwall, Enalapril
treatment increases cardiac performance and energy reserve via the creatine
kinase reaction in myocardium of Syrian myopathic hamsters with advanced
heart failure, Circulation 91 (1995) 1824–1833.
[113] R. Tian, L. Nascimben, R. Kaddurah-Daouk, J.S. Ingwall, Depletion of energy
reserve via the creatine kinase reaction during the evolution of heart failure in
cardiomyopathic hamsters, J. Mol. Cell. Cardiol. 28 (1996) 755–765.
[114] J.S. Ingwall, Energy metabolism in heart failure and remodelling, Cardiovasc. Res.
81 (2009) 412–419.
[115] J.S. Ingwall, R.G. Weiss, Is the failing heart energy starved? On using chemical
energy to support cardiac function, Circ. Res. 95 (2004) 135–145.
[116] S. Neubauer, T. Krahe, R. Schindler, M. Horn, H. Hillenbrand, C. Entzeroth, H.
Mader, E.P. Kromer, G.A. Riegger, K. Lackner, 31P magnetic resonance
spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered
cardiac high-energy phosphate metabolism in heart failure, Circulation 86
(1992) 1810–1818.
[117] A. Clerk, T.E. Cullingford, S.J. Fuller, A. Giraldo, T. Markou, S. Pikkarainen, P.H.
Sugden, Signaling pathways mediating cardiac myocyte gene expression in
physiological and stress responses, J. Cell. Physiol. 212 (2007) 311–322.
[118] C. Depre, G.L. Shipley, W. Chen, Q. Han, T. Doenst, M.L. Moore, S. Stepkowski, P.J.
Davies, H. Taegtmeyer, Unloaded heart in vivo replicates fetal gene expression of
cardiac hypertrophy, Nat. Med. 4 (1998) 1269–1275.
[119] B.H. Lorell, W. Grossman, Cardiac hypertrophy: the consequences for diastole, J.
Am. Coll. Cardiol. 9 (1987) 1189–1193.
[120] M. van Bilsen, P.J. Smeets, A.J. Gilde, G.J. van der Vusse, Metabolic remodelling of
the failing heart: the cardiac burn-out syndrome? Cardiovasc. Res. 61 (2004)
218–226.
[121] P. Razeghi, M.E. Young, J.L. Alcorn, C.S. Moravec, O.H. Frazier, H. Taegtmeyer,
Metabolic gene expression in fetal and failing human heart, Circulation 104
(2001) 2923–2931.
[122] M.F. Allard, B.O. Schonekess, S.L. Henning, D.R. English, G.D. Lopaschuk,
Contribution of oxidative metabolism and glycolysis to ATP production in
hypertrophied hearts, Am. J. Physiol. 267 (1994) H742–H750.
[123] B.O. Schonekess, M.F. Allard, S.L. Henning, R.B. Wambolt, G.D. Lopaschuk,
Contribution of glycogen and exogenous glucose to glucose metabolism during
ischemia in the hypertrophied rat heart, Circ. Res. 81 (1997) 540–549.
[124] R.B. Wambolt, S.L. Henning, D.R. English, Y. Dyachkova, G.D. Lopaschuk, M.F.
Allard, Glucose utilization and glycogen turnover are accelerated in hypertro-
phied rat hearts during severe low-ﬂow ischemia, J. Mol. Cell. Cardiol. 31 (1999)
493–502.
[125] Z. El Alaoui-Talibi, A. Guendouz, M. Moravec, J. Moravec, Control of oxidative
metabolism in volume-overloaded rat hearts: effect of propionyl-L-carnitine,
Am. J. Physiol. 272 (1997) H1615–H1624.
[126] Z. el Alaoui-Talibi, S. Landormy, A. Loireau, J. Moravec, Fatty acid oxidation and
mechanical performance of volume-overloaded rat hearts, Am. J. Physiol. 262
(1992) H1068–H1074.
[127] T.J. Aitman, A.M. Glazier, C.A. Wallace, L.D. Cooper, P.J. Norsworthy, F.N. Wahid,
K.M. Al-Majali, P.M. Trembling, C.J. Mann, C.C. Shoulders, D. Graf, E. St Lezin, T.W.
Kurtz, V. Kren, M. Pravenec, A. Ibrahimi, N.A. Abumrad, L.W. Stanton, J. Scott,
Identiﬁcation of CD36 (FAT) as an insulin-resistance gene causing defective fatty
acid and glucose metabolism in hypertensive rats, Nat. Genet. 21 (1999) 76–83.
[128] G.J. van der Vusse, M. van Bilsen, J.F. Glatz, Cardiac fatty acid uptake and
transport in health and disease, Cardiovasc. Res. 45 (2000) 279–293.
[129] J.A. Madrazo, D.P. Kelly, The PPAR trio: regulators of myocardial energy
metabolism in health and disease, J. Mol. Cell. Cardiol. 44 (2008) 968–975.
[130] P.J. Smeets, B.E. Teunissen, P.H. Willemsen, F.A. van Nieuwenhoven, A.E. Brouns,
B.J. Janssen, J.P. Cleutjens, B. Staels, G.J. van der Vusse, M. van Bilsen, Cardiac
hypertrophy is enhanced in PPAR alpha−/− mice in response to chronic
pressure overload, Cardiovasc. Res. 78 (2008) 79–89.
[131] M.E. Young, S. Patil, J. Ying, C. Depre, H.S. Ahuja, G.L. Shipley, S.M. Stepkowski, P.J.
Davies, H. Taegtmeyer, Uncoupling protein 3 transcription is regulated by
peroxisome proliferator-activated receptor (alpha) in the adult rodent heart,
FASEB J. 15 (2001) 833–845.
[132] F. Liang, F. Wang, S. Zhang, D.G. Gardner, Peroxisome proliferator activated
receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac
myocytes, Endocrinology 144 (2003) 4187–4194.
[133] P.J. Smeets, B.E. Teunissen, A. Planavila, H. de Vogel-van den Bosch, P.H.
Willemsen, G.J. van der Vusse, M. van Bilsen, Inﬂammatory pathways are
activated during cardiomyocyte hypertrophy and attenuated by peroxisomeproliferator-activated receptors PPARalpha and PPARdelta, J. Biol. Chem. 283
(2008) 29109–29118.
[134] B.N. Finck, J.J. Lehman, T.C. Leone, M.J. Welch, M.J. Bennett, A. Kovacs, X. Han, R.W.
Gross, R. Kozak, G.D. Lopaschuk, D.P. Kelly, The cardiac phenotype induced by
PPARalpha overexpression mimics that caused by diabetes mellitus, J. Clin. Invest.
109 (2002) 121–130.
[135] B.N. Finck, X. Han, M. Courtois, F. Aimond, J.M. Nerbonne, A. Kovacs, R.W. Gross,
D.P. Kelly, A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis
of diabetic cardiomyopathy: modulation by dietary fat content, Proc. Natl Acad.
Sci. USA 100 (2003) 1226–1231.
[136] L. Cheng, G. Ding, Q. Qin, Y. Huang, W. Lewis, N. He, R.M. Evans, M.D. Schneider,
F.A. Brako, Y. Xiao, Y.E. Chen, Q. Yang, Cardiomyocyte-restricted peroxisome
proliferator-activated receptor-delta deletion perturbs myocardial fatty acid
oxidation and leads to cardiomyopathy, Nat. Med. 10 (2004) 1245–1250.
[137] E.M. Burkart, N. Sambandam, X. Han, R.W. Gross, M. Courtois, C.M. Gierasch, K.
Shoghi, M.J. Welch, D.P. Kelly, Nuclear receptors PPARbeta/delta and PPARalpha
direct distinct metabolic regulatory programs in the mouse heart, J. Clin. Invest.
117 (2007) 3930–3939.
[138] G.D. Barish, V.A. Narkar, R.M. Evans, PPAR delta: a dagger in the heart of the
metabolic syndrome, J. Clin. Invest. 116 (2006) 590–597.
[139] C.H. Lee, P. Olson, A. Hevener, I. Mehl, L.W. Chong, J.M. Olefsky, F.J. Gonzalez, J.
Ham, H. Kang, J.M. Peters, R.M. Evans, PPARdelta regulates glucose metabolism
and insulin sensitivity, Proc. Natl Acad. Sci. USA 103 (2006) 3444–3449.
[140] N. Sambandam, G.D. Lopaschuk, R.W. Brownsey, M.F. Allard, Energy metabolism
in the hypertrophied heart, Heart Fail. Rev. 7 (2002) 161–173.
[141] M.R. Morissette, A.L. Howes, T. Zhang, J. Heller Brown, Upregulation of GLUT1
expression is necessary for hypertrophy and survival of neonatal rat cardio-
myocytes, J. Mol. Cell. Cardiol. 35 (2003) 1217–1227.
[142] A. Keller, J.D. Rouzeau, F. Farhadian, C. Wisnewsky, F. Marotte, N. Lamande, J.L.
Samuel, K. Schwartz, M. Lazar, M. Lucas, Differential expression of alpha- and
beta-enolase genes during rat heart development and hypertrophy, Am. J.
Physiol. 269 (1995) H1843–H1851.
[143] H. Degens, K.F. de Brouwer, A.J. Gilde, M. Lindhout, P.H. Willemsen, B.J. Janssen,
G.J. van der Vusse, M. van Bilsen, Cardiac fatty acid metabolism is preserved in
the compensated hypertrophic rat heart, Basic Res. Cardiol. 101 (2006) 17–26.
[144] K.F. de Brouwer, H. Degens, W.M. Aartsen, M. Lindhout, N.J. Bitsch, A.J. Gilde, P.H.
Willemsen, B.J. Janssen, G.J. van der Vusse, M. van Bilsen, Speciﬁc and sustained
down-regulation of genes involved in fatty acid metabolism is not a hallmark of
progression to cardiac failure in mice, J. Mol. Cell. Cardiol. 40 (2006) 838–845.
[145] J.M. O'Donnell, A.D. Fields, N. Sorokina, E.D. Lewandowski, The absence of
endogenous lipid oxidation in early stage heart failure exposes limits in lipid
storage and turnover, J. Mol. Cell. Cardiol. 44 (2008) 315–322.
[146] M.P. Chandler, J. Kerner, H. Huang, E. Vazquez, A. Reszko, W.Z. Martini, C.L.
Hoppel, M. Imai, S. Rastogi, H.N. Sabbah, W.C. Stanley, Moderate severity heart
failure does not involve a downregulation ofmyocardial fatty acid oxidation, Am.
J. Physiol. Heart Circ. Physiol. 287 (2004) H1538–H1543.
[147] M. Grover-McKay, M. Schwaiger, J. Krivokapich, J.K. Perloff, M.E. Phelps, H.R.
Schelbert, Regional myocardial blood ﬂow and metabolism at rest in mildly
symptomatic patients with hypertrophic cardiomyopathy, J. Am. Coll. Cardiol. 13
(1989) 317–324.
[148] J. Lommi, M. Kupari, H. Yki-Jarvinen, Free fatty acid kinetics and oxidation in
congestive heart failure, Am. J. Cardiol. 81 (1998) 45–50.
[149] G. Paolisso, A. Gambardella, D. Galzerano, A. D'Amore, P. Rubino, M. Verza, P.
Teasuro, M. Varricchio, F. D'Onofrio, Total-body and myocardial substrate
oxidation in congestive heart failure, Metabolism 43 (1994) 174–179.
[150] M. Taylor, T.R. Wallhaus, T.R. Degrado, D.C. Russell, P. Stanko, R.J. Nickles, C.K.
Stone, An evaluation of myocardial fatty acid and glucose uptake using PET with
[18F]ﬂuoro-6-thia-heptadecanoic acid and [18F]FDG in patients with congestive
heart failure, J. Nucl. Med. 42 (2001) 55–62.
[151] H. Bugger, M. Schwarzer, D. Chen, A. Schrepper, P.A. Amorim, M. Schoepe, T.D.
Nguyen, F.W. Mohr, O. Khalimonchuk, B.C. Weimer, T. Doenst, Proteomic
remodelling of mitochondrial oxidative pathways in pressure overload-induced
heart failure, Cardiovasc. Res. 85 (2010) 376–384.
[152] T. Doenst, G. Pytel, A. Schrepper, P. Amorim, G. Farber, Y. Shingu, F.W. Mohr, M.
Schwarzer, Decreased rates of substrate oxidation ex vivo predict the onset of
heart failure and contractile dysfunction in rats with pressure overload,
Cardiovasc. Res. 86 (2010) 461–470.
[153] B. Lei, V. Lionetti, M.E. Young, M.P. Chandler, C. d'Agostino, E. Kang, M. Altarejos,
K. Matsuo, T.H. Hintze, W.C. Stanley, F.A. Recchia, Paradoxical downregulation of
the glucose oxidation pathway despite enhanced ﬂux in severe heart failure, J.
Mol. Cell. Cardiol. 36 (2004) 567–576.
[154] J.C. Osorio, W.C. Stanley, A. Linke, M. Castellari, Q.N. Diep, A.R. Panchal, T.H.
Hintze, G.D. Lopaschuk, F.A. Recchia, Impaired myocardial fatty acid oxidation
and reduced protein expression of retinoid X receptor-alpha in pacing-induced
heart failure, Circulation 106 (2002) 606–612.
[155] K. Qanud, M. Mamdani, M. Pepe, R.J. Khairallah, J. Gravel, B. Lei, S.A. Gupte, V.G.
Sharov, H.N. Sabbah, W.C. Stanley, F.A. Recchia, Reverse changes in cardiac
substrate oxidation in dogs recovering from heart failure, Am. J. Physiol. Heart
Circ. Physiol. 295 (2008) H2098–H2105.
[156] D. Neglia, A. De Caterina, P. Marraccini, A. Natali, M. Ciardetti, C. Vecoli, A.
Gastaldelli, D. Ciociaro, P. Pellegrini, R. Testa, L. Menichetti, A. L'Abbate, W.C.
Stanley, F.A. Recchia, Impaired myocardial metabolic reserve and substrate
selection ﬂexibility during stress in patients with idiopathic dilated cardiomy-
opathy, Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H3270–H3278.
[157] H. Tuunanen, E. Engblom, A. Naum, K. Nagren, B. Hesse, K.E. Airaksinen, P.
Nuutila, P. Iozzo, H. Ukkonen, L.H. Opie, J. Knuuti, Free fatty acid depletion
1348 J.S. Jaswal et al. / Biochimica et Biophysica Acta 1813 (2011) 1333–1350acutely decreases cardiac work and efﬁciency in cardiomyopathic heart failure,
Circulation 114 (2006) 2130–2137.
[158] H. Taegtmeyer, Metabolism—the lost child of cardiology, J. Am. Coll. Cardiol. 36
(2000) 1386–1388.
[159] V.J. Dzau, W.S. Colucci, N.K. Hollenberg, G.H. Williams, Relation of the renin–
angiotensin–aldosterone system to clinical state in congestive heart failure,
Circulation 63 (1981) 645–651.
[160] R.N. Re, Mechanisms of disease: local renin–angiotensin–aldosterone systems
and the pathogenesis and treatment of cardiovascular disease, Nat. Clin. Pract.
Cardiovasc. Med. 1 (2004) 42–47.
[161] G.S. Pepper, R.W. Lee, Sympathetic activation in heart failure and its treatment
with beta-blockade, Arch. Intern. Med. 159 (1999) 225–234.
[162] M.J. Morris, H.S. Cox, G.W. Lambert, D.M. Kaye, G.L. Jennings, I.T. Meredith, M.D.
Esler, Region-speciﬁc neuropeptide Y overﬂows at rest and during sympathetic
activation in humans, Hypertension 29 (1997) 137–143.
[163] G. Fellander, L. Eleborg, J. Bolinder, J. Nordenstrom, P. Arner, Microdialysis of
adipose tissue during surgery: effect of local alpha- and beta-adrenoceptor
blockade on blood ﬂow and lipolysis, J. Clin. Endocrinol. Metab. 81 (1996)
2919–2924.
[164] B. Brisse, P. Tetsch, W. Jacobs, F. Bender, Beta-adrenoceptor blockade in stress
due to oral surgery, Br. J. Clin. Pharmacol. 13 (1982) 421S–427S.
[165] R.J. Newman, Comparison of the antilipolytic effect of metoprolol, acebutolol,
and propranolol in man, Br. Med. J. 2 (1977) 601–603.
[166] N. Igarashi, T. Nozawa, N. Fujii, T. Suzuki, A. Matsuki, T. Nakadate, A. Igawa, H.
Inoue, Inﬂuence of beta-adrenoceptor blockade on the myocardial accumulation
of fatty acid tracer and its intracellular metabolism in the heart after ischemia–
reperfusion injury, Circ. J. 70 (2006) 1509–1514.
[167] T.R. Wallhaus, M. Taylor, T.R. DeGrado, D.C. Russell, P. Stanko, R.J. Nickles, C.K.
Stone, Myocardial free fatty acid and glucose use after carvedilol treatment in
patients with congestive heart failure, Circulation 103 (2001) 2441–2446.
[168] E.J. Eichhorn, J.B. Bedotto, C.R. Malloy, B.A. Hatﬁeld, D. Deitchman, M. Brown, J.E.
Willard, P.A. Grayburn, Effect of beta-adrenergic blockade on myocardial
function and energetics in congestive heart failure. Improvements in hemody-
namic, contractile, and diastolic performance with bucindolol, Circulation 82
(1990) 473–483.
[169] E.J. Eichhorn, C.M. Heesch, J.H. Barnett, L.G. Alvarez, S.M. Fass, P.A. Grayburn, B.A.
Hatﬁeld, L.G. Marcoux, C.R. Malloy, Effect of metoprolol on myocardial function
and energetics in patients with nonischemic dilated cardiomyopathy: a
randomized, double-blind, placebo-controlled study, J. Am. Coll. Cardiol. 24
(1994) 1310–1320.
[170] M. Bohm, K. La Rosee, R.H. Schwinger, E. Erdmann, Evidence for reduction of
norepinephrine uptake sites in the failing human heart, J. Am. Coll. Cardiol. 25
(1995) 146–153.
[171] S. Engelhardt, M. Bohm, E. Erdmann, M.J. Lohse, Analysis of beta-adrenergic
receptor mRNA levels in human ventricular biopsy specimens by quantitative
polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor
mRNA in heart failure, J. Am. Coll. Cardiol. 27 (1996) 146–154.
[172] J.R. Neely, M. Whitmer, S. Mochizuki, Effects of mechanical activity and
hormones on myocardial glucose and fatty acid utilization, Circ. Res. 38 (1976)
I22–I30.
[173] K. Nonogaki, New insights into sympathetic regulation of glucose and fat
metabolism, Diabetologia 43 (2000) 533–549.
[174] A.G. Marangou, F.P. Alford, G. Ward, F. Liskaser, P.M. Aitken, K.M. Weber, R.C.
Boston, J.D. Best, Hormonal effects of norepinephrine on acute glucose disposal
in humans: a minimal model analysis, Metabolism 37 (1988) 885–891.
[175] J. Arnlov, L. Lind, B. Zethelius, B. Andren, C.N. Hales, B. Vessby, H. Lithell, Several
factors associated with the insulin resistance syndrome are predictors of left
ventricular systolic dysfunction in a male population after 20 years of follow-up,
Am. Heart J. 142 (2001) 720–724.
[176] K.F. Petersen, S. Dufour, D.B. Savage, S. Bilz, G. Solomon, S. Yonemitsu, G.W. Cline,
D. Befroy, L. Zemany, B.B. Kahn, X. Papademetris, D.L. Rothman, G.I. Shulman, The
role of skeletal muscle insulin resistance in the pathogenesis of the metabolic
syndrome, Proc. Natl Acad. Sci. USA 104 (2007) 12587–12594.
[177] G.I. Shulman, D.L. Rothman, T. Jue, P. Stein, R.A. DeFronzo, R.G. Shulman,
Quantitation of muscle glycogen synthesis in normal subjects and subjects with
non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectros-
copy, N. Engl. J. Med. 322 (1990) 223–228.
[178] W. Doehner, S. von Haehling, S.D. Anker, Insulin resistance in chronic heart
failure, J. Am. Coll. Cardiol. 52 (2008) 2398 author reply 239–240.
[179] D.P. Dutka, M. Pitt, D. Pagano, M.Mongillo, D. Gathercole, R.S. Bonser, P.G. Camici,
Myocardial glucose transport and utilization in patients with type 2 diabetes
mellitus, left ventricular dysfunction, and coronary artery disease, J. Am. Coll.
Cardiol. 48 (2006) 2225–2231.
[180] L.A. Nikolaidis, D. Elahi, T. Hentosz, A. Doverspike, R. Huerbin, L. Zourelias, C.
Stolarski, Y.T. Shen, R.P. Shannon, Recombinant glucagon-like peptide-1
increases myocardial glucose uptake and improves left ventricular performance
in conscious dogs with pacing-induced dilated cardiomyopathy, Circulation 110
(2004) 955–961.
[181] L.A. Nikolaidis, D. Elahi, Y.T. Shen, R.P. Shannon, Active metabolite of GLP-1
mediates myocardial glucose uptake and improves left ventricular performance
in conscious dogs with dilated cardiomyopathy, Am. J. Physiol. Heart Circ.
Physiol. 289 (2005) H2401–H2408.
[182] E. Aasum, D.D. Belke, D.L. Severson, R.A. Riemersma, M. Cooper, M. Andreassen, T.S.
Larsen, Cardiac function and metabolism in Type 2 diabetic mice after treatment
with BM 17.0744, a novel PPAR-alpha activator, Am. J. Physiol. Heart Circ. Physiol.
283 (2002) H949–H957.[183] E. Aasum, A.D. Hafstad, D.L. Severson, T.S. Larsen, Age-dependent changes in
metabolism, contractile function, and ischemic sensitivity in hearts from db/db
mice, Diabetes 52 (2003) 434–441.
[184] E. Aasum, A.M. Khalid, O.A. Gudbrandsen, O.J. How, R.K. Berge, T.S. Larsen,
Fenoﬁbrate modulates cardiac and hepatic metabolism and increases ischemic
tolerance in diet-induced obese mice, J. Mol. Cell. Cardiol. 44 (2008) 201–209.
[185] J. Buchanan, P.K. Mazumder, P. Hu, G. Chakrabarti, M.W. Roberts, U.J. Yun, R.C.
Cooksey, S.E. Litwin, E.D. Abel, Reduced cardiac efﬁciency and altered substrate
metabolism precedes the onset of hyperglycemia and contractile dysfunction in
two mouse models of insulin resistance and obesity, Endocrinology 146 (2005)
5341–5349.
[186] A.D. Hafstad, G.H. Solevag, D.L. Severson, T.S. Larsen, E. Aasum, Perfused hearts
from Type 2 diabetic (db/db) mice show metabolic responsiveness to insulin,
Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H1763–H1769.
[187] O.J. How, E. Aasum, S. Kunnathu, D.L. Severson, E.S. Myhre, T.S. Larsen, Inﬂuence
of substrate supply on cardiac efﬁciency, as measured by pressure–volume
analysis in ex vivo mouse hearts, Am. J. Physiol. Heart Circ. Physiol. 288 (2005)
H2979–H2985.
[188] L.R. Peterson, P. Herrero, K.B. Schechtman, S.B. Racette, A.D. Waggoner, Z.
Kisrieva-Ware, C. Dence, S. Klein, J. Marsala, T. Meyer, R.J. Gropler, Effect of
obesity and insulin resistance on myocardial substrate metabolism and
efﬁciency in young women, Circulation 109 (2004) 2191–2196.
[189] J.R. Ussher, T.R. Koves, J.S. Jaswal, L. Zhang, O. Ilkayeva, J.R. Dyck, D.M. Muoio, G.D.
Lopaschuk, Insulin-stimulated cardiac glucose oxidation is increased in high-fat
diet-induced obese mice lackingmalonyl CoA decarboxylase, Diabetes 58 (2009)
1766–1775.
[190] A.J. Liedtke, B. Renstrom, T.A. Hacker, S.H. Nellis, Effects of moderate repetitive
ischemia on myocardial substrate utilization, Am. J. Physiol. 269 (1995)
H246–H253.
[191] J.R. Neely, A.J. Liedtke, J.T. Whitmer, M.J. Rovetto, Relationship between coronary
ﬂow and adenosine triphosphate production from glycolysis and oxidative
metabolism, Recent Adv. Stud. Card. Struct. Metab. 8 (1975) 301–321.
[192] A.K. Jonassen, E. Aasum, R.A. Riemersma, O.D. Mjos, T.S. Larsen, Glucose–insulin–
potassium reduces infarct size when administered during reperfusion, Cardio-
vasc. Drugs Ther. 14 (2000) 615–623.
[193] D. Sodi-Pallares, M.R. Testelli, B.L. Fishleder, A. Bisteni, G.A. Medrano, C.
Friedland, A. De Micheli, Effects of an intravenous infusion of a potassium–
glucose–insulin solution on the electrocardiographic signs of myocardial
infarction. A preliminary clinical report, Am. J. Cardiol. 9 (1962) 166–181.
[194] H.X. Zhang, Y.M. Zang, J.H. Huo, S.J. Liang, H.F. Zhang, Y.M. Wang, Q. Fan, W.Y.
Guo, H.C. Wang, F. Gao, Physiologically tolerable insulin reduces myocardial
injury and improves cardiac functional recovery in myocardial ischemic/
reperfused dogs, J. Cardiovasc. Pharmacol. 48 (2006) 306–313.
[195] R. Diaz, E.A. Paolasso, L.S. Piegas, C.D. Tajer, M.G. Moreno, R. Corvalan, J.E. Isea, G.
Romero, Metabolic modulation of acute myocardial infarction. The ECLA
(Estudios Cardiologicos Latinoamerica) Collaborative Group, Circulation 98
(1998) 2227–2234.
[196] I.C. van der Horst, F. Zijlstra, A.W. van't Hof, C.J. Doggen, M.J. de Boer, H.
Suryapranata, J.C. Hoorntje, J.H. Dambrink, R.O. Gans, H.J. Bilo, Glucose–insulin–
potassium infusion inpatients treated with primary angioplasty for acute
myocardial infarction: the glucose–insulin–potassium study: a randomized
trial, J. Am. Coll. Cardiol. 42 (2003) 784–791.
[197] C.D. Folmes, A.S. Clanachan, G.D. Lopaschuk, Fatty acids attenuate insulin
regulation of 5′-AMP-activated protein kinase and insulin cardioprotection after
ischemia, Circ. Res. 99 (2006) 61–68.
[198] R.A. Kloner, K. Przyklenk, T. Shook, C.P. Cannon, Protection conferred by
preinfarct angina is manifest in the aged heart: evidence from the TIMI 4 trial, J.
Thromb. Thrombolysis 6 (1998) 89–92.
[199] K. Malmberg, L. Ryden, A. Hamsten, J. Herlitz, A. Waldenstrom, H. Wedel, Effects
of insulin treatment on cause-speciﬁc one-year mortality and morbidity in
diabetic patients with acute myocardial infarction. DIGAMI Study Group.
Diabetes Insulin-Glucose in Acute Myocardial Infarction, Eur. Heart J. 17
(1996) 1337–1344.
[200] L. Ceremuzynski, A. Budaj, A. Czepiel, T. Burzykowski, P. Achremczyk, W.
Smielak-Korombel, J. Maciejewicz, J. Dziubinska, E. Nartowicz, T. Kawka-
Urbanek, W. Piotrowski, J. Hanzlik, A. Cieslinski, K. Kawecka-Jaszcz, J. Gessek,
K. Wrabec, Low-dose glucose–insulin–potassium is ineffective in acute myocar-
dial infarction: results of a randomized multicenter Pol-GIK trial, Cardiovasc.
Drugs Ther. 13 (1999) 191–200.
[201] I.C. van der Horst, J.R. Timmer, J.P. Ottervanger, H.J. Bilo, R.O. Gans, M.J. de Boer, F.
Zijlstra, Glucose–insulin–potassium and reperfusion in acute myocardial
infarction: rationale and design of the Glucose–Insulin–Potassium Study-2
(GIPS-2), Am. Heart J. 149 (2005) 585–591.
[202] A.R. Panchal, W.C. Stanley, J. Kerner, H.N. Sabbah, Beta-receptor blockade
decreases carnitine palmitoyl transferase I activity in dogs with heart failure, J.
Card. Fail. 4 (1998) 121–126.
[203] M. Podbregar, G. Voga, Effect of selective and nonselective beta-blockers on
resting energy production rate and total body substrate utilization in chronic
heart failure, J. Card. Fail. 8 (2002) 369–378.
[204] A. Al-Hesayen, E.R. Azevedo, J.S. Floras, S. Hollingshead, G.D. Lopaschuk, J.D.
Parker, Selective versus nonselective beta-adrenergic receptor blockade in
chronic heart failure: differential effects on myocardial energy substrate
utilization, Eur. J. Heart Fail. 7 (2005) 618–623.
[205] W.S. Cook, A.V. Yeldandi, M.S. Rao, T. Hashimoto, J.K. Reddy, Less extrahepatic
induction of fatty acid beta-oxidation enzymes by PPAR alpha, Biochem. Biophys.
Res. Commun. 278 (2000) 250–257.
1349J.S. Jaswal et al. / Biochimica et Biophysica Acta 1813 (2011) 1333–1350[206] K. Schoonjans, B. Staels, P. Grimaldi, J. Auwerx, Acyl-CoA synthetase mRNA
expression is controlled by ﬁbric-acid derivatives, feeding and liver proliferation,
Eur. J. Biochem. 216 (1993) 615–622.
[207] N.S. Wayman, Y. Hattori, M.C. McDonald, H. Mota-Filipe, S. Cuzzocrea, B. Pisano,
P.K. Chatterjee, C. Thiemermann, Ligands of the peroxisome proliferator-
activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct
size, FASEB J. 16 (2002) 1027–1040.
[208] M.R. Prasad, R. Clement, H. Otani, R. Jones, D.K. Das, R.M. Engelman, R.H. Breyer, J.
A. Rousou, Improved myocardial performance induced by cloﬁbrate during
reperfusion after acute myocardial infarction, Can. J. Physiol. Pharmacol. 66
(1988) 1518–1523.
[209] A.J. Gilde, K.A. van der Lee, P.H. Willemsen, G. Chinetti, F.R. van der Leij, G.J. van
der Vusse, B. Staels, M. van Bilsen, Peroxisome proliferator-activated receptor
(PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the
expression of genes involved in cardiac lipid metabolism, Circ. Res. 92 (2003)
518–524.
[210] E. Hondares, I. Pineda-Torra, R. Iglesias, B. Staels, F. Villarroya, M. Giralt,
PPARdelta, but not PPARalpha, activates PGC-1alpha gene transcription in
muscle, Biochem. Biophys. Res. Commun. 354 (2007) 1021–1027.
[211] C. Pellieux, C. Montessuit, I. Papageorgiou, R. Lerch, Angiotensin II downregulates
the fatty acid oxidation pathway in adult rat cardiomyocytes via release of
tumour necrosis factor-alpha, Cardiovasc. Res. 82 (2009) 341–350.
[212] A. Planavila, J.C. Laguna, M. Vazquez-Carrera, Nuclear factor-kappaB activation
leads to down-regulation of fatty acid oxidation during cardiac hypertrophy, J.
Biol. Chem. 280 (2005) 17464–17471.
[213] R.J. Sidell, M.A. Cole, N.J. Draper, M. Desrois, R.E. Buckingham, K. Clarke,
Thiazolidinedione treatment normalizes insulin resistance and ischemic injury
in the Zucker Fatty rat heart, Diabetes 51 (2002) 1110–1117.
[214] P. Zhu, L. Lu, Y. Xu, G.G. Schwartz, Troglitazone improves recovery of left ventricular
function after regional ischemia in pigs, Circulation 101 (2000) 1165–1171.
[215] T.L. Yue, W. Bao, J.L. Gu, J. Cui, L. Tao, X.L. Ma, E.H. Ohlstein, B.M. Jucker,
Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with
ameliorated cardiac insulin resistance and protection from ischemia/reperfu-
sion-induced myocardial injury, Diabetes 54 (2005) 554–562.
[216] T.L. Yue, W. Bao, B.M. Jucker, J.L. Gu, A.M. Romanic, P.J. Brown, J. Cui, D.T.
Thudium, R. Boyce, C.L. Burns-Kurtis, R.C. Mirabile, K. Aravindhan, E.H. Ohlstein,
Activation of peroxisome proliferator-activated receptor-alpha protects the
heart from ischemia/reperfusion injury, Circulation 108 (2003) 2393–2399.
[217] O.J. How, T.S. Larsen, A.D. Hafstad, A. Khalid, E.S. Myhre, A.J. Murray, N.T.
Boardman, M. Cole, K. Clarke, D.L. Severson, E. Aasum, Rosiglitazone treatment
improves cardiac efﬁciency in hearts from diabetic mice, Arch. Physiol. Biochem.
113 (2007) 211–220.
[218] N.H. Son, T.S. Park, H. Yamashita, M. Yokoyama, L.A. Huggins, K. Okajima, S.
Homma, M.J. Szabolcs, L.S. Huang, I.J. Goldberg, Cardiomyocyte expression of
PPARgamma leads to cardiac dysfunction in mice, J. Clin. Invest. 117 (2007)
2791–2801.
[219] J. Lindenfeld, F.A. Masoudi, Fluid retention with thiazolidinediones: does the
mechanism inﬂuence the outcome? J. Am. Coll. Cardiol. 49 (2007) 1705–1707.
[220] J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, I.K.
Moules, A.M. Skene, M.H. Tan, P.J. Lefebvre, G.D. Murray, E. Standl, R.G. Wilcox, L.
Wilhelmsen, J. Betteridge, K. Birkeland, A. Golay, R.J. Heine, L. Koranyi, M. Laakso,
M. Mokan, A. Norkus, V. Pirags, T. Podar, A. Scheen, W. Scherbaum, G.
Schernthaner, O. Schmitz, J. Skrha, U. Smith, J. Taton, Secondary prevention of
macrovascular events in patients with type 2 diabetes in the PROactive Study
(PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised
controlled trial, Lancet 366 (2005) 1279–1289.
[221] S.E. Nissen, K. Wolski, Effect of rosiglitazone on the risk of myocardial infarction
and death from cardiovascular causes, N. Engl. J. Med. 356 (2007) 2457–2471.
[222] S.E. Nissen, K. Wolski, Rosiglitazone revisited: an updated meta-analysis of risk
for myocardial infarction and cardiovascular mortality, Arch. Intern. Med. (June
28 2010)8 [Epub ahead of print].
[223] G.M. Reaven, H. Chang, B.B. Hoffman, Additive hypoglycemic effects of drugs that
modify free-fatty acid metabolism by different mechanisms in rats with
streptozocin-induced diabetes, Diabetes 37 (1988) 28–32.
[224] G.D. Lopaschuk, G.F. McNeil, J.J. McVeigh, Glucose oxidation is stimulated in
reperfused ischemic hearts with the carnitine palmitoyltransferase 1 inhibitor,
Etomoxir, Mol. Cell Biochem 88 (1989) 175–179.
[225] G.D. Lopaschuk, M.A. Spafford, N.J. Davies, S.R. Wall, Glucose and palmitate
oxidation in isolated working rat hearts reperfused after a period of transient
global ischemia, Circ. Res. 66 (1990) 546–553.
[226] G.D. Lopaschuk, S.R. Wall, P.M. Olley, N.J. Davies, Etomoxir, a carnitine
palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced
ischemic injury independent of changes in long chain acylcarnitine, Circ. Res.
63 (1988) 1036–1043.
[227] F.J. Schmitz, P. Rosen, H. Reinauer, Improvement of myocardial function and
metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor
Etomoxir, Horm. Metab. Res. 27 (1995) 515–522.
[228] S.R. Wall, G.D. Lopaschuk, Glucose oxidation rates in fatty acid-perfused isolated
working hearts from diabetic rats, Biochim. Biophys. Acta 1006 (1989) 97–103.
[229] M. Turcani, H. Rupp, Etomoxir improves left ventricular performance of
pressure-overloaded rat heart, Circulation 96 (1997) 3681–3686.
[230] H. Rupp, R. Vetter, Sarcoplasmic reticulum function and carnitine palmitoyl-
transferase-1 inhibition during progression of heart failure, Br. J. Pharmacol. 131
(2000) 1748–1756.
[231] S. Schmidt-Schweda, C. Holubarsch, First clinical trial with etomoxir in patients
with chronic congestive heart failure, Clin. Sci. (Lond) 99 (2000) 27–35.[232] C.J. Holubarsch, M. Rohrbach, M. Karrasch, E. Boehm, L. Polonski, P. Ponikowski,
S. Rhein, A double-blind randomized multicentre clinical trial to evaluate the
efﬁcacy and safety of two doses of etomoxir in comparison with placebo in
patients with moderate congestive heart failure: the ERGO (etomoxir for the
recovery of glucose oxidation) study, Clin. Sci. (Lond) 113 (2007) 205–212.
[233] P.L. Cole, A.D. Beamer, N. McGowan, C.O. Cantillon, K. Benfell, R.A. Kelly, L.H.
Hartley, T.W. Smith, E.M. Antman, Efﬁcacy and safety of perhexiline maleate in
refractory angina. A double-blind placebo-controlled clinical trial of a novel
antianginal agent, Circulation 81 (1990) 1260–1270.
[234] L. Lee, R. Campbell, M. Scheuermann-Freestone, R. Taylor, P. Gunaruwan, L.
Williams, H. Ashraﬁan, J. Horowitz, A.G. Fraser, K. Clarke, M. Frenneaux,
Metabolic modulation with perhexiline in chronic heart failure: a randomized,
controlled trial of short-term use of a novel treatment, Circulation 112 (2005)
3280–3288.
[235] K. Abozguia, P. Elliott, W. McKenna, T.T. Phan, G. Nallur-Shivu, I. Ahmed, A.R.
Maher, K. Kaur, J. Taylor, A. Henning, H. Ashraﬁan, H. Watkins, M. Frenneaux,
Metabolic modulator perhexiline corrects energy deﬁciency and improves
exercise capacity in symptomatic hypertrophic cardiomyopathy, Circulation 122
(2010) 1562–1569.
[236] J.F. Cheng, M. Chen, D. Wallace, S. Tith, M. Haramura, B. Liu, C.C. Mak, T.
Arrhenius, S. Reily, S. Brown, V. Thorn, C. Harmon, R. Barr, J.R. Dyck, G.D.
Lopaschuk, A.M. Nadzan, Synthesis and structure–activity relationship of small-
molecule malonyl coenzyme A decarboxylase inhibitors, J. Med. Chem. 49
(2006) 1517–1525.
[237] J.F. Cheng, Y. Huang, R. Penuliar, M. Nishimoto, L. Liu, T. Arrhenius, G. Yang, E.
O'Leary, M. Barbosa, R. Barr, J.R. Dyck, G.D. Lopaschuk, A.M. Nadzan, Discovery of
potent and orally available malonyl-CoA decarboxylase inhibitors as cardiopro-
tective agents, J. Med. Chem. 49 (2006) 4055–4058.
[238] J.R. Dyck, J.F. Cheng, W.C. Stanley, R. Barr, M.P. Chandler, S. Brown, D. Wallace, T.
Arrhenius, C. Harmon, G. Yang, A.M. Nadzan, G.D. Lopaschuk, Malonyl coenzyme
A decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid
oxidation and stimulating glucose oxidation, Circ. Res. 94 (2004) e78–e84.
[239] W.C. Stanley, E.E. Morgan, H. Huang, T.A. McElfresh, J.P. Sterk, I.C. Okere, M.P.
Chandler, J. Cheng, J.R. Dyck, G.D. Lopaschuk, Malonyl-CoA decarboxylase
inhibition suppresses fatty acid oxidation and reduces lactate production during
demand-induced ischemia, Am. J. Physiol. Heart Circ. Physiol. 289 (2005)
H2304–H2309.
[240] J.F. Cheng, C.C. Mak, Y. Huang, R. Penuliar, M. Nishimoto, L. Zhang, M. Chen, D.
Wallace, T. Arrhenius, D. Chu, G. Yang,M. Barbosa, R. Barr, J.R. Dyck, G.D. Lopaschuk,
A.M. Nadzan, Heteroaryl substituted bis-triﬂuoromethyl carbinols as malonyl-CoA
decarboxylase inhibitors, Bioorg. Med. Chem. Lett. 16 (2006) 3484–3488.
[241] P.F. Kantor, A. Lucien, R. Kozak, G.D. Lopaschuk, The antianginal drug
trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to
glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme
A thiolase, Circ. Res. 86 (2000) 580–588.
[242] G.D. Lopaschuk, R. Barr, P.D. Thomas, J.R. Dyck, Beneﬁcial effects of trimetazidine
in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation
secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase, Circ. Res.
93 (2003) e33–e37.
[243] A. MacInnes, D.A. Fairman, P. Binding, J. Rhodes, M.J. Wyatt, A. Phelan, P.S.
Haddock, E.H. Karran, The antianginal agent trimetazidine does not exert its
functional beneﬁt via inhibition of mitochondrial long-chain 3-ketoacyl
coenzyme A thiolase, Circ. Res. 93 (2003) e26–e32.
[244] R. Saeedi, M. Grist, R.B. Wambolt, A. Bescond-Jacquet, A. Lucien, M.F. Allard,
Trimetazidine normalizes postischemic function of hypertrophied rat hearts, J.
Pharmacol. Exp. Ther. 314 (2005) 446–454.
[245] B. Liu, A.S. Clanachan, R. Schulz, G.D. Lopaschuk, Cardiac efﬁciency is improved
after ischemia by altering both the source and fate of protons, Circ. Res. 79
(1996) 940–948.
[246] A. Ciapponi, R. Pizarro, J. Harrison, Trimetazidine for stable angina, Cochrane
Database Syst. Rev. (2005) CD003614.
[247] P.G. Steg, G. Grollier, P. Gallay, M. Morice, G.J. Karrillon, H. Benamer, C. Kempf, T.
Laperche, P. Arnaud, P. Sellier, C. Bourguignon, C. Harpey, A randomized double-
blind trial of intravenous trimetazidine as adjunctive therapy to primary
angioplasty for acute myocardial infarction, Int. J. Cardiol. 77 (2001) 263–273.
[248] J.M. Detry, P. Sellier, S. Pennaforte, D. Cokkinos, H. Dargie, P. Mathes,
Trimetazidine: a new concept in the treatment of angina. Comparison with
propranolol in patients with stable angina. Trimetazidine European Multicenter
Study Group, Br. J. Clin. Pharmacol. 37 (1994) 279–288.
[249] H. Szwed, Z. Sadowski, W. Elikowski, A. Koronkiewicz, A. Mamcarz, W. Orszulak,
E. Skibinska, K. Szymczak, J. Swiatek, M.Winter, Combination treatment in stable
effort angina using trimetazidine and metoprolol: results of a randomized,
double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand, Eur.
Heart J. 22 (2001) 2267–2274.
[250] G. Fragasso, G. Perseghin, F. De Cobelli, A. Esposito, A. Palloshi, G. Lattuada, P.
Scifo, G. Calori, A. Del Maschio, A. Margonato, Effects of metabolic modulation by
trimetazidine on left ventricular function and phosphocreatine/adenosine
triphosphate ratio in patients with heart failure, Eur. Heart J. 27 (2006) 942–948.
[251] G. Fragasso, A. Palloshi, P. Puccetti, C. Silipigni, A. Rossodivita, M. Pala, G. Calori, O.
Alﬁeri, A. Margonato, A randomized clinical trial of trimetazidine, a partial free
fatty acid oxidation inhibitor, in patients with heart failure, J. Am. Coll. Cardiol.
48 (2006) 992–998.
[252] H. Tuunanen, E. Engblom, A. Naum, K. Nagren, M. Scheinin, B. Hesse, K.E. Juhani
Airaksinen, P. Nuutila, P. Iozzo, H. Ukkonen, L.H. Opie, J. Knuuti, Trimetazidine, a
metabolic modulator, has cardiac and extracardiac beneﬁts in idiopathic dilated
cardiomyopathy, Circulation 118 (2008) 1250–1258.
1350 J.S. Jaswal et al. / Biochimica et Biophysica Acta 1813 (2011) 1333–1350[253] J.G. McCormack, V.E. Baracos, R. Barr, G.D. Lopaschuk, Effects of ranolazine on
oxidative substrate preference in epitrochlearis muscle, J. Appl. Physiol. 81
(1996) 905–910.
[254] J.G. McCormack, R.L. Barr, A.A. Wolff, G.D. Lopaschuk, Ranolazine stimulates
glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts,
Circulation 93 (1996) 135–142.
[255] B. Clarke, M. Spedding, L. Patmore, J.G. McCormack, Protective effects of ranolazine
in guinea-pig hearts during low-ﬂow ischaemia and their association with
increases in active pyruvate dehydrogenase, Br. J. Pharmacol. 109 (1993) 748–750.
[256] B. Clarke, K.M. Wyatt, J.G. McCormack, Ranolazine increases active pyruvate
dehydrogenase in perfused normoxic rat hearts: evidence for an indirect
mechanism, J. Mol. Cell. Cardiol. 28 (1996) 341–350.
[257] K.M. Wyatt, C. Skene, K. Veitch, L. Hue, J.G. McCormack, The antianginal agent
ranolazine is a weak inhibitor of the respiratory complex I, but with greater
potency in broken or uncoupled than in coupled mitochondria, Biochem.
Pharmacol. 50 (1995) 1599–1606.
[258] H. Fraser, L. Belardinelli, L. Wang, P.E. Light, J.J. McVeigh, A.S. Clanachan,
Ranolazine decreases diastolic calcium accumulation caused by ATX-II or
ischemia in rat hearts, J. Mol. Cell. Cardiol. 41 (2006) 1031–1038.
[259] S. Sossalla, S. Wagner, E.C. Rasenack, H. Ruff, S.L. Weber, F.A. Schondube, T.
Tirilomis, G. Tenderich, G. Hasenfuss, L. Belardinelli, L.S. Maier, Ranolazine
improves diastolic dysfunction in isolated myocardium from failing human
hearts—role of late sodium current and intracellular ion accumulation, J. Mol.
Cell. Cardiol. 45 (2008) 32–43.
[260] L. Belardinelli, J.C. Shryock, H. Fraser, Inhibition of the late sodium current as a
potential cardioprotective principle: effects of the late sodium current inhibitor
ranolazine, Heart 92 (Suppl 4) (2006) iv6–iv14.
[261] P. Wang, H. Fraser, S.G. Lloyd, J.J. McVeigh, L. Belardinelli, J.C. Chatham, A
comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid
oxidation, on cardiac metabolism and left ventricular function in rat isolated
perfused heart during ischemia and reperfusion, J. Pharmacol. Exp. Ther. 321
(2007) 213–220.
[262] S.L. Hale, R.A. Kloner, Ranolazine, an inhibitor of the late sodium channel current,
reduces postischemic myocardial dysfunction in the rabbit, J. Cardiovasc.
Pharmacol. Ther. 11 (2006) 249–255.
[263] S.L. Hale, J.A. Leeka, R.A. Kloner, Improved left ventricular function and reduced
necrosis after myocardial ischemia/reperfusion in rabbits treated with ranola-
zine, an inhibitor of the late sodium channel, J. Pharmacol. Exp. Ther. 318 (2006)
418–423.
[264] M.P. Chandler, W.C. Stanley, H. Morita, G. Suzuki, B.A. Roth, B. Blackburn, A.
Wolff, H.N. Sabbah, Short-term treatment with ranolazine improves mechanical
efﬁciency in dogs with chronic heart failure, Circ. Res. 91 (2002) 278–280.
[265] H.N. Sabbah, M.P. Chandler, T. Mishima, G. Suzuki, P. Chaudhry, O. Nass, B.J.
Biesiadecki, B. Blackburn, A. Wolff, W.C. Stanley, Ranolazine, a partial fatty acid
oxidation (pFOX) inhibitor, improves left ventricular function in dogs with
chronic heart failure, J. Card. Fail. 8 (2002) 416–422.
[266] S. Rastogi, V.G. Sharov, S. Mishra, R.C. Gupta, B. Blackburn, L. Belardinelli, W.C.
Stanley, H.N. Sabbah, Ranolazine combined with enalapril or metoprolol
prevents progressive LV dysfunction and remodeling in dogs with moderate
heart failure, Am. J. Physiol. Heart Circ. Physiol. 295 (2008) H2149–H2155.
[267] B.R. Chaitman, S.L. Skettino, J.O. Parker, P. Hanley, J. Meluzin, J. Kuch, C.J. Pepine,
W.Wang, J.J. Nelson, D.A. Hebert, A.A. Wolff, Anti-ischemic effects and long-term
survival during ranolazine monotherapy in patients with chronic severe angina,
J. Am. Coll. Cardiol. 43 (2004) 1375–1382.
[268] M.F. Rousseau, H. Pouleur, G. Cocco, A.A. Wolff, Comparative efﬁcacy of
ranolazine versus atenolol for chronic angina pectoris, Am. J. Cardiol. 95
(2005) 311–316.
[269] B.R. Chaitman, C.J. Pepine, J.O. Parker, J. Skopal, G. Chumakova, J. Kuch, W. Wang,
S.L. Skettino, A.A. Wolff, Effects of ranolazine with atenolol, amlodipine, or
diltiazem on exercise tolerance and angina frequency in patients with severe
chronic angina: a randomized controlled trial, JAMA 291 (2004) 309–316.
[270] P.H. Stone, N.A. Gratsiansky, A. Blokhin, I.Z. Huang, L. Meng, Antianginal efﬁcacy
of ranolazine when added to treatment with amlodipine: the ERICA (Efﬁcacy of
Ranolazine in Chronic Angina) trial, J. Am. Coll. Cardiol. 48 (2006) 566–575.
[271] B.M. Scirica, D.A. Morrow, H. Hod, S.A. Murphy, L. Belardinelli, C.M. Hedgepeth, P.
Molhoek, F.W. Verheugt, B.J. Gersh, C.H. McCabe, E. Braunwald, Effect of
ranolazine, an antianginal agent with novel electrophysiological properties, on
the incidence of arrhythmias in patients with non ST-segment elevation acute
coronary syndrome: results from the Metabolic Efﬁciency With Ranolazine for
Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in
Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial,
Circulation 116 (2007) 1647–1652.
[272] T. Itoi, L. Huang, G.D. Lopaschuk, Glucose use in neonatal rabbit hearts reperfused
after global ischemia, Am. J. Physiol. 265 (1993) H427–H433.
[273] W.C. Stanley, L.A. Hernandez, D. Spires, J. Bringas, S. Wallace, J.G. McCormack,
Pyruvate dehydrogenase activity andmalonyl CoA levels in normal and ischemic
swine myocardium: effects of dichloroacetate, J. Mol. Cell. Cardiol. 28 (1996)
905–914.
[274] T.A. Nicholl, G.D. Lopaschuk, J.H. McNeill, Effects of free fatty acids and
dichloroacetate on isolated working diabetic rat heart, Am. J. Physiol. 261
(1991) H1053–H1059.
[275] J. Gamble, G.D. Lopaschuk, Glycolysis and glucose oxidation during reperfusion of
ischemic hearts from diabetic rats, Biochim. Biophys. Acta 1225 (1994) 191–199.
[276] T.J. Wargovich, R.G. MacDonald, J.A. Hill, R.L. Feldman, P.W. Stacpoole, C.J. Pepine,
Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary
artery disease, Am. J. Cardiol. 61 (1988) 65–70.[277] T. Kato, S. Niizuma, Y. Inuzuka, T. Kawashima, J. Okuda, Y. Tamaki, Y. Iwanaga, M.
Narazaki, T. Matsuda, T. Soga, T. Kita, T. Kimura, T. Shioi, Analysis of metabolic
remodeling in compensated left ventricular hypertrophy and heart failure, Circ.
Heart Fail 3 (2010) 420–430.
[278] M. Gandhi, B.A. Finegan, A.S. Clanachan, Role of glucose metabolism in the
recovery of postischemic LV mechanical function: effects of insulin and other
metabolic modulators, Am. J. Physiol. Heart Circ. Physiol. 294 (2008)
H2576–H2586.
[279] E.D. Lewandowski, L.T. White, Pyruvate dehydrogenase inﬂuences postischemic
heart function, Circulation 91 (1995) 2071–2079.
[280] G.D. Lopaschuk, R.B. Wambolt, R.L. Barr, An imbalance between glycolysis and
glucose oxidation is a possible explanation for the detrimental effects of high
levels of fatty acids during aerobic reperfusion of ischemic hearts, J. Pharmacol.
Exp. Ther. 264 (1993) 135–144.
[281] H. Schoder, R.J. Knight, K.F. Kofoed, H.R. Schelbert, D.B. Buxton, Regulation of
pyruvate dehydrogenase activity and glucose metabolism in post-ischaemic
myocardium, Biochim. Biophys. Acta 1406 (1998) 62–72.
[282] R.B. Wambolt, G.D. Lopaschuk, R.W. Brownsey, M.F. Allard, Dichloroacetate
improves postischemic function of hypertrophied rat hearts, J. Am. Coll. Cardiol.
36 (2000) 1378–1385.
[283] T.D. Aicher, R.C. Anderson, G.R. Bebernitz, G.M. Coppola, C.F. Jewell, D.C. Knorr, C.
Liu, D.M. Sperbeck, L.J. Brand, R.J. Strohschein, J. Gao, C.C. Vinluan, S.S. Shetty, C.
Dragland, E.L. Kaplan, D. DelGrande, A. Islam, X. Liu, R.J. Lozito, W.M. Maniara, R.E.
Walter, W.R. Mann, (R)-3, 3, 3-Triﬂuoro-2-hydroxy-2-methylpropionamides are
orally active inhibitors of pyruvate dehydrogenase kinase, J. Med. Chem. 42 (1999)
2741–2746.
[284] G.R. Bebernitz, T.D. Aicher, J.L. Stanton, J. Gao, S.S. Shetty, D.C. Knorr, R.J.
Strohschein, J. Tan, L.J. Brand, C. Liu, W.H. Wang, C.C. Vinluan, E.L. Kaplan, C.J.
Dragland, D. DelGrande, A. Islam, R.J. Lozito, X. Liu, W.M. Maniara, W.R. Mann,
Anilides of (R)-triﬂuoro-2-hydroxy-2-methylpropionic acid as inhibitors of
pyruvate dehydrogenase kinase, J. Med. Chem. 43 (2000) 2248–2257.
[285] J.A. Morrell, J. Orme, R.J. Butlin, T.E. Roche, R.M. Mayers, E. Kilgour, AZD7545 is a
selective inhibitor of pyruvate dehydrogenase kinase 2, Biochem. Soc. Trans. 31
(2003) 1168–1170.
[286] F. Labarthe, R. Gelinas, C. Des Rosiers, Medium-chain fatty acids as metabolic
therapy in cardiac disease, Cardiovasc. Drugs Ther. 22 (2008) 97–106.
[287] K.E. Sundqvist, K.H. Vuorinen, K.J. Peuhkurinen, I.E. Hassinen, Metabolic effects of
propionate, hexanoate and propionylcarnitine in normoxia, ischaemia and
reperfusion. Does an anaplerotic substrate protect the ischaemic myocardium?
Eur. Heart J. 15 (1994) 561–570.
[288] I.C. Okere, T.A. McElfresh, D.Z. Brunengraber, W. Martini, J.P. Sterk, H. Huang, M.P.
Chandler, H. Brunengraber, W.C. Stanley, Differential effects of heptanoate and
hexanoate on myocardial citric acid cycle intermediates following ischemia–
reperfusion, J. Appl. Physiol. 100 (2006) 76–82.
[289] T. Hajri, A. Ibrahimi, C.T. Coburn, F.F. Knapp Jr., T. Kurtz, M. Pravenec, N.A.
Abumrad, Defective fatty acid uptake in the spontaneously hypertensive rat is a
primary determinant of altered glucose metabolism, hyperinsulinemia, and
myocardial hypertrophy, J. Biol. Chem. 276 (2001) 23661–23666.
[290] M. Iemitsu, N. Shimojo, S. Maeda, Y. Irukayama-Tomobe, S. Sakai, T. Ohkubo, Y.
Tanaka, T. Miyauchi, The beneﬁt of medium-chain triglyceride therapy on the
cardiac function of SHRs is associated with a reversal of metabolic and signaling
alterations, Am. J. Physiol. Heart Circ. Physiol. 295 (2008) H136–H144.
[291] N. Shimojo, T. Miyauchi, M. Iemitsu, Y. Irukayama-Tomobe, S. Maeda, T. Ohkubo, Y.
Tanaka, K. Goto, I. Yamaguchi, Effects of medium-chain triglyceride (MCT)
application to SHR on cardiac function, hypertrophy and expression of endothelin-
1 mRNA and other genes, J. Cardiovasc. Pharmacol. 44 (Suppl 1) (2004) S181–S185.
[292] F. Labarthe, M. Khairallah, B. Bouchard, W.C. Stanley, C. Des Rosiers, Fatty acid
oxidation and its impact on response of spontaneously hypertensive rat hearts to
an adrenergic stress: beneﬁts of a medium-chain fatty acid, Am. J. Physiol. Heart
Circ. Physiol. 288 (2005) H1425–H1436.
[293] G.D. Lopaschuk, C.D. Folmes, W.C. Stanley, Cardiac energy metabolism in obesity,
Circ. Res. 101 (2007) 335–347.
[294] J.D. McGarry, R.L. Dobbins, Fatty acids, lipotoxicity and insulin secretion,
Diabetologia 42 (1999) 128–138.
[295] J.E. Schaffer, Lipotoxicity: when tissues overeat, Curr. Opin. Lipidol. 14 (2003)
281–287.
[296] R.H. Unger, Lipotoxic diseases, Annu. Rev. Med. 53 (2002) 319–336.
[297] R.H. Unger, Minireview: weapons of lean body mass destruction: the role of
ectopic lipids in the metabolic syndrome, Endocrinology 144 (2003) 5159–5165.
[298] H. Yagyu, G. Chen, M. Yokoyama, K. Hirata, A. Augustus, Y. Kako, T. Seo, Y. Hu, E.P.
Lutz, M. Merkel, A. Bensadoun, S. Homma, I.J. Goldberg, Lipoprotein lipase (LpL)
on the surface of cardiomyocytes increases lipid uptake and produces a
cardiomyopathy, J. Clin. Invest. 111 (2003) 419–426.
[299] M. Yokoyama, H. Yagyu, Y. Hu, T. Seo, K. Hirata, S. Homma, I.J. Goldberg,
Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-
speciﬁc lipoprotein lipase transgenic mouse, J. Biol. Chem. 279 (2004) 4204–4211.
[300] Y.T. Zhou, P. Grayburn, A. Karim, M. Shimabukuro, M. Higa, D. Baetens, L. Orci, R.
H. Unger, Lipotoxic heart disease in obese rats: implications for human obesity,
Proc. Natl Acad. Sci. USA 97 (2000) 1784–1789.
[301] M. Saddik, J. Gamble, L.A. Witters, G.D. Lopaschuk, Acetyl-CoA carboxylase
regulation of fatty acid oxidation in the heart, J. Biol. Chem. 268 (1993)
25836–25845.
[302] I.C. Okere, M.P. Chandler, T.A. McElfresh, J.H. Rennison, T.A. Kung, B.D. Hoit, P.
Ernsberger, M.E. Young, W.C. Stanley, Carnitine palmitoyl transferase-I inhibi-
tion is not associated with cardiac hypertrophy in rats fed a high-fat diet, Clin.
Exp. Pharmacol. Physiol. 34 (2007) 113–119.
